UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

 

FORM 10-K

 

☒

ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

 

 

For the fiscal year ended December 31, 2022

 

 

☐

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

Commission File No. 0-18105

_____________________

 

vaso_10kimg1.jpg

 

VASO CORPORATION

(Exact name of registrant as specified in Its Charter)

 

Delaware

 

11-2871434

(State or other jurisdiction of

incorporation or organization)

 

(IRS Employer

Identification No.)

 

 

 

137 Commercial Street, Plainview, New York

 

11803

(Address of Principal Executive Offices)

 

(Zip Code)

 

Registrant’s telephone number, including area code:(516) 997-4600

 

Securities registered under Section 12(b) of the Act:  None

 

Title of each class

Trading Symbol

Name of each exchange on which registered

 

Securities registered under Section 12(g) of the Act:

 

Common Stock, $.001 par value

(Title of Class)

 

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ☐ No ☒

 

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes ☐ No ☒

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the past 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files) Yes ☒ No ☐

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer

☐

Accelerated filer

☐

Non-accelerated Filer

☒

Smaller reporting company

☒

Emerging growth company

☐

 

 

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. ☐

 

If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. ☐

 

Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant’s executive officers during the relevant recovery period pursuant to §240.10D-1(b). ☐

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

 

The aggregate market value of common stock held by non-affiliates was approximately $8.7 million based on the closing sales price of the common stock as quoted on the OTC PK on June 30, 2022.

 

At March 24, 2023, the number of shares outstanding of the issuer’s common stock was 175,127,878.

 

DOCUMENTS INCORPORATED BY REFERENCE

 

None.

 

Audit firm ID  1195

 

 

 

  

{THIS PAGE LEFT INTENTIONALLY BLANK}

 

 

 

  

VASO CORPORATION

INDEX TO FORM 10-K

 

 

 

 

Page

 

 

 

 

 

 

PART I

 

2

 

ITEM 1 – BUSINESS

 

2

 

ITEM 1A - RISK FACTORS

 

7

 

ITEM 2 – PROPERTIES

 

12

 

 

 

 

 

 

PART II

 

13

 

ITEM 5 – MARKET FOR REGISTRANT’S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES

 

13

 

ITEM 7 – MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

 

13

 

ITEM 8 - FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA

 

19

 

ITEM 9A - CONTROLS AND PROCEDURES

 

19

 

ITEM 9B – OTHER INFORMATION

 

21

 

 

 

 

 

 

PART III

 

22

 

ITEM 10 – DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE.

 

22

 

ITEM 11 - EXECUTIVE COMPENSATION

 

25

 

ITEM 12 - SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS

 

27

 

ITEM 13 - CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE

 

28

 

ITEM 14 - PRINCIPAL ACCOUNTING FEES AND SERVICES

 

29

 

 

 

 

 

 

PART IV

 

30

 

ITEM 15 – EXHIBITS AND FINANCIAL STATEMENT SCHEDULES

 

30

 

 

 

 

 

 

SIGNATURES

 

32

 

 

 

 

 

 

INDEX TO CONSOLIDATED FINANCIAL STATEMENTS

 

F-1

 

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

 

F-2

 

CONSOLIDATED BALANCE SHEETS

 

F-6

 

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME.

 

F-7

 

CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY

 

F-8

 

CONSOLIDATED STATEMENTS OF CASH FLOWS

 

F-9

 

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

 

F-10

 

 

 

 

 

 

 

EXHIBITS

 

 

 

 

 

 

 

 

Exhibit 31

Certifications Pursuant to Securities Exchange Act Rule 13A-14(A)/15D-14(A)

 

 

 

Exhibit 32

Certifications Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

 

 

 

 

 
- i -

Table of Contents

 

PART I

 

ITEM 1 – BUSINESS

 

Except for historical information contained in this report, the matters discussed are forward-looking statements that involve risks and uncertainties. When used in this report, words such as “anticipates”, “believes”, “could”, “estimates”, “expects”, “may”, “plans”, “potential” and “intends” and similar expressions, as they relate to the Company or its management, identify forward-looking statements. Such forward-looking statements are based on the beliefs of the Company’s management, as well as assumptions made by and information currently available to the Company’s management. Among the factors that could cause actual results to differ materially are the following: the effect of business and economic conditions, including the possibility of a downturn in the U.S. economy and continued effects of the COVID-19 pandemic; the effect of the dramatic changes taking place in IT and healthcare; continuation of the GEHC agreement; the impact of competitive technology and products and their pricing; medical insurance reimbursement policies; unexpected manufacturing or supplier problems; unforeseen difficulties and delays in product development programs; the actions of regulatory authorities and third-party payers in the United States and overseas; and the risk factors reported from time to time in the Company’s SEC reports.  The Company undertakes no obligation to update forward-looking statements as a result of future events or developments.

 

Unless the context requires otherwise, all references to “we”, “our”, “us”, “Company”, “registrant”, “Vaso” or “management” refer to Vaso Corporation and its subsidiaries.

 

General Overview

 

                Vaso Corporation principally operates in three distinct business segments in the healthcare equipment and information technology industries.  We manage and evaluate our operations, and report our financial results, through these three business segments.

 

 

·

IT segment, operating through a wholly-owned subsidiary VasoTechnology, Inc., primarily focuses on healthcare IT and managed network technology services;

 

 

 

 

·

Professional sales service segment, operating through a wholly-owned subsidiary Vaso Diagnostics, Inc. d/b/a VasoHealthcare, primarily focuses on the sale of healthcare capital equipment for GE HealthCare (“GEHC”) into the health provider middle market; and

 

 

 

 

·

Equipment segment, primarily focuses on the design, manufacture, sale and service of proprietary medical devices and software, operating through a wholly-owned subsidiary VasoMedical, Inc., which in turn operates through Vasomedical Solutions, Inc. for domestic business and Vasomedical Global Corp. for international business, respectively.

 

VasoTechnology

 

VasoTechnology, Inc. was formed in May 2015, at the time the Company acquired all of the assets of NetWolves, LLC and its affiliates, including the membership interests in NetWolves Network Services, LLC  (collectively, “NetWolves”).  It currently consists of a managed network and security service division (NetWolves) and a healthcare IT application VAR (value added reseller) division (VasoHealthcare IT).  Its current offering includes:

 

 

·

Managed diagnostic imaging applications (channel partner of select vendors of healthcare IT products).

 

·

Managed network infrastructure (routers, switches and other core equipment).

 

·

Managed network transport (FCC licensed carrier reselling 175+ facility partners).

 

·

Managed security services.

 

VasoTechnology uses a combination of proprietary technology, methodology and best-in-class third-party applications to deliver its value proposition.

 

 
2

Table of Contents

 

VasoHealthcare

 

VasoHealthcare commenced operations in 2010, in conjunction with the Company’s execution of its exclusive sales representation agreement with GEHC, which at the time was the healthcare business division of the General Electric Company (“GE”), to further the sale of certain medical capital equipment in certain domestic market segments.  Its current offering consists of:

 

 

·

GEHC diagnostic imaging equipment and ultrasound systems.

 

·

GEHC service agreements for the above equipment.

 

·

GEHC training services for use of the above equipment.

 

·

GEHC and third-party financial services for the above equipment.

 

VasoHealthcare has built a team of over 75 highly experienced sales professionals who utilize proprietary sales management and analytic tools to manage the complete sales process and to increase market penetration.

 

VasoMedical

 

The proprietary medical equipment business under VasoMedical dates back to 1995 when the Company began the proprietary Enhanced External Counterpulsation (EECP®) technology in the United States, and has since diversified to include other medical hardware and software.  Vasomedical Global was formed in 2011 to combine and coordinate the various international operations including design, development, manufacturing, and sales of medical devices and software, while domestic activities are conducted under Vasomedical Solutions.  These devices and software primarily consist of cardiovascular diagnostic and therapeutic applications, including:

 

 

·

Biox™ series Holter monitors and ambulatory blood pressure recorders.

 

·

ARCS® series analysis, reporting and communication software for ECG and blood pressure signals, including cloud-based software suite and algorithm subscription services.

 

·

MobiCare® multi-parameter wireless vital-sign monitoring system.

 

·

EECP® therapy systems for non-invasive, outpatient treatment of ischemic heart disease.

 

This segment uses its extensive in-house knowledge for cardiovascular devices and software coupled with its engineering resources to cost effectively create and market its proprietary technology. It sells and services its products to customers in the U.S. and China directly and sells and/or services its products in the international market mainly through independent distributors.

 

Historical Background

 

Vaso Corporation was incorporated in Delaware in July 1987. For most of its history, the Company primarily was a single-product company designing, manufacturing, marketing and servicing its proprietary Enhanced External Counterpulsation, or EECP®, therapy systems, mainly for the treatment of angina. In 2010 it began to diversify its business operations. The Company changed its name to Vaso Corporation in 2016 to more accurately reflect the diversified nature of its business, and continues to use the original name VasoMedical for its proprietary medical device subsidiary.

 

In May 2010, the Company launched its Professional Sales Service business through a wholly-owned subsidiary Vaso Diagnostics, Inc. d/b/a VasoHealthcare, which was appointed by GEHC as its exclusive representative for the sale of select GEHC diagnostic imaging equipment to specific market segments in the 48 contiguous states of the United States and the District of Columbia.  The original agreement (“GEHC Agreement”) was for three years ending June 30, 2013; it has been extended several times with the current extension through December 31, 2026, subject to earlier termination under certain conditions.

 

In June 2014, the Company began its IT segment business by concluding the Value Added Reseller Agreement (“VAR Agreement”) with GEHC to become a national value added reseller of GEHC Digital’s software solutions such as Picture Archiving and Communication System (“PACS”), Radiology Information System (“RIS”), and related services, including implementation, training, management and support.  This business focuses primarily on customer segments currently served by VasoHealthcare.  A new wholly owned subsidiary, VasoHealthcare IT Corp. (“VHC IT”), was formed to conduct the healthcare IT business.

 

 
3

Table of Contents

 

In May 2015, the Company further expanded its IT business segment by acquiring all of the assets of NetWolves, LLC and its affiliates, including the membership interests in NetWolves Network Services, LLC (collectively, “NetWolves”), pursuant to an asset purchase agreement.  NetWolves designs and delivers efficient and cost-effective multi-network and multi-technology solutions as a managed network provider, as well as provides a complete single-source solution that includes design, network redundancy, application device management, real-time network monitoring, reporting and support systems as a comprehensive solution. 

 

The Company’s Equipment business also has been significantly expanded from the original EECP®-only operations.  In September 2011, the Company acquired FGE, a British Virgin Islands company, which owned or controlled two Chinese operating companies - Life Enhancement Technology Ltd. (“LET”) and Biox Instruments Co. Ltd. (“Biox”) - to expand its technical and manufacturing capabilities and to enhance its distribution network, technology, and product portfolio.  Biox was a variable interest entity (“VIE”) controlled by FGE through certain contracts and an option to acquire all the shares of Biox by FGE’s wholly owned subsidiary Gentone, and in March 2019 Gentone exercised its option to acquire all of the shares of Biox. In August 2014, the Company through Gentone acquired all of the outstanding shares of Genwell Instruments Co. Ltd. (“Genwell”), which was formed in 2010 to develop the MobiCare® wireless multi-parameter patient monitoring system and holds intellectual property rights for this system. As a result, the Company has expanded its equipment products portfolio to include Biox™ series ambulatory patient monitoring systems, ARCS® series software for ECG and blood pressure analysis, and the MobiCare® patient monitoring device.       

 

In April 2014, the Company entered into a cooperation agreement with Chongqing PSK-Health Sci-Tech Development Co., Ltd. (“PSK”) of Chongqing, China, the leading manufacturer of external counter pulsation, or ECP, therapy systems in China, to form a joint venture company, VSK Medical Limited (“VSK”), a Cayman Islands company, for the global marketing, sale and advancement of ECP therapy technology.  The Company owned 49.9% of VSK, which commenced operations in January 2015.  In March 2018, the Company terminated the cooperation agreement with PSK and sold its shares in VSK to PSK.  On May 20, 2020, the Company closed on the sale of 51% of the capital stock of its wholly-owned subsidiary EECP Global Corporation (“EECP Global”) to PSK.  EECP Global was formed in September 2019 to hold all the assets and liabilities of its EECP business. Concurrently with the closing of the transaction, the Company signed Management Service Agreement with EECP Global to provide management service for the business and operation of EECP Global in the United States. The agreement provides an initial term of three years starting April 1, 2020, the effective date of the sale, which is automatically renewable for additional one-year terms.  Pursuant to the agreement, EECP Global reimburses the Company all direct expenses and pays a monthly management fee during the term of the agreement.

 

Management

 

The Company currently bases its headquarters in Plainview, Long Island, NY pursuant to a lease which expires in September 2025.  Reporting to the Board of Directors, corporate officers of the Company include the President and Chief Executive Officer (“CEO”), Co-Chief Financial Officer and Secretary, Chief Operating Officer (“COO”), and Co-Chief Financial Officer and Treasurer.

 

The management of the Company’s IT segment is led by the COO of the Company, who is also the President of VasoTechnology and NetWolves, which is based in Tampa, FL.  Our VasoHealthcare IT business is organized as a part of VasoTechnology and is also led by the COO, supported by several software solution sales and implementation specialists, based in Nashville, TN. The business unit works with our VasoHealthcare diagnostic imaging equipment sales team to generate leads and potential clients for the software solutions products and works with NetWolves sales and technical teams for comprehensive IT product and service offerings.

 

In the professional sales services segment, we sell GEHC diagnostic imaging products to our assigned market through a nationwide team of approximately 65 sales employees led by several regional managers and an executive team who report to the President of VasoHealthcare. The operation is also supported by in-house administrative, analytic and other support staff, as well as applicable GEHC employees.

 

 
4

Table of Contents

 

The equipment segment is under the direct supervision of the CEO of the Company. Sales and marketing efforts in the domestic market are led by a Vice President of national sales and service at Vasomedical Solutions, and the managers of our China subsidiaries, based in Wuxi, China, are in charge of the development and production of all our proprietary products and marketing and sales in China and the international markets.  We sell our Biox™ series and other products in China by a group of sales managers as well as through distributors covering various regions of China and other international geographies.

 

Competition

 

In the U.S. diagnostic imaging market where we sell GEHC products, our main competitors include Siemens, Philips, Canon, and Hologic. Key competitive factors in the market include price, quality, finance availability, delivery speed, service and support, innovation, distribution network, breadth of product and service offerings and brand name recognition. GEHC is a leading competitor in this market.

 

In the IT segment, our primary competitors in the healthcare IT VAR business are Agfa Healthcare, McKesson, Philips, Carestream Health and other independent software providers. Key competitive factors are brand recognition, quality, radiology workflow solutions, scalability and service and support capability.  In the managed network services business our primary competition includes, but is not limited to, organizations who have a presence in most of the major markets for the following products and services: network services, managed services, security services and healthcare applications. Several of those competitors, many of which are our vendors, are: Verizon, AT&T, CenturyLink, IBM and Cisco Resellers, Siemens, Epic, small regional IT integrators and large company internal IT departments.  

 

In the ambulatory monitoring system business, there are numerous competitors of various size and strength.  The Biox™ series is among the few from China with CE Mark certification for Europe, CFDA approval for China, US FDA clearances as well as Brazilian Agencia Nacional de Vigilancia Sanitaria (ANVISA) approval, which are among the most important qualifications to market and sell the products around the world.

 

Regulations on Medical Devices

 

As a medical device manufacturer and marketer, we are subject to extensive regulation by numerous government regulatory agencies, including the US FDA and similar foreign agencies.  We are required to comply with applicable laws, regulations and standards governing the development, preclinical and clinical testing, manufacturing, quality testing, labeling, promotion, import, export, and distribution of our medical devices. 

 

Compliance with Regulations in the United States

 

The Company has received appropriate US FDA premarket notification (510(k)) clearance for all its products marketed and sold in the United States, including EECP® therapy systems and Biox™ ambulatory monitoring systems and analysis and report software.  We continue to seek US FDA clearance or approval for new products prior to their introduction to the US market.

 

We are subject to other US FDA regulations that apply prior to and after a product is commercially released.  We also are subject to periodic and random inspections by the US FDA for compliance with the current Good Manufacturing Practice, or cGMP, requirements and Quality System Regulation.  The US FDA also enforces post-marketing controls that include the requirement to submit medical device reports to the agency when a manufacturer becomes aware of information suggesting that any adverse events are related to its marketed products.  The FDA relies on medical device reports to identify product problems and utilizes these reports to determine, among other things, whether it should exercise its enforcement powers.  The FDA also may require post-market surveillance studies for specified devices.

 

We are subject to the Federal Food, Drug, and Cosmetic Act’s, or FDCA’s, general controls, including establishment registration, device listing, and labeling requirements. 

 

The sales and advertising of our products is subject to regulation by the Federal Trade Commission, or FTC.  The FTC Act prohibits unfair or deceptive acts or practices in or affecting commerce.  Violations of the FTC Act, such as failure to have substantiation for product claims, would subject us to a variety of enforcement actions, including compulsory process, cease and desist orders and injunctions, which can require, among other things, limits on advertising, corrective advertising, consumer redress and restitution, as well as substantial fines or other penalties.

 

 
5

Table of Contents

 

As a medical device sales channel partner and product reseller to healthcare facilities, we are subject to various federal, state and local laws targeting fraud and abuse in the healthcare industry, including anti-kickback and false claims laws.

 

Foreign Regulation

 

In most countries where we seek to export our medical devices, a local regulatory clearance must be obtained.  The regulatory review process varies from country to country and can be complex, costly, uncertain, and time-consuming.  Our medical devices are all manufactured in accordance with ISO 13485 (Medical device – Quality management systems – Requirement for regulatory purpose), an internationally agreed standard that sets out the requirements for a quality management system specific to the medical devices industry.  All our current medical devices have obtained necessary clearances or approvals prior to their release in the appropriate jurisdictions, including CE marking certification for European Union countries, China FDA (CFDA) approval for mainland China, Korean FDA (KFDA) approval for South Korea, Agência Nacional de Vigilncia Sanitária (ANVISA) approval for Brazil, Taiwan FDA (TFDA) for Taiwan,  and the Saudi SFDA (MDMA) for the Kingdom of Saudi Arabia.

 

We are also subject to audits by organizations authorized by foreign countries to determine compliance with laws, regulations and standards that apply to the commercialization of our products in those markets.  Examples include auditing by a European Union Notified Body organization (authorized by a member state’s Competent Authority) to determine conformity with the Medical Device Directives (MDD) and by an organization authorized by the Brazilian government to determine conformity with the ANVISA requirement.

 

Patient Privacy

 

Federal and state laws protect the confidentiality of certain patient health information, including patient records, and restrict the use and disclosure of that protected information.  The U.S. Department of Health and Human Services (HHS) published patient privacy rules under the Health Insurance Portability and Accountability Act of 1996 (HIPAA privacy rule) and the regulation was finalized in October 2002.  Currently, the HIPAA privacy rule affects us only indirectly in that patient data that we access, collect and analyze may include protected health information.  Additionally, we have signed some Business Associate Agreements with Covered Entities that contractually bind us to protect private health information, consistent with the HIPAA privacy rules requirements.  We do not expect the costs and impact of the HIPAA privacy rule to be material to our business.

 

Regulations in the IT Business

 

As a reseller of telecommunication services and network solutions provider, our products and services are subject to federal, state and local regulations. These regulations govern, in part, our rates and the way we conduct our business, including the requirement to offer telecommunications services pursuant to nondiscriminatory rates, terms, and conditions, the obligation to safeguard the confidentiality of customer proprietary network information, as well as the obligation to maintain specialized records and file reports with the Federal Communications Commission  and state regulatory authorities. While we believe we are in compliance with laws and regulations in jurisdictions where we do business, we continue to monitor and assess our compliance.

 

The Federal Communications Commission (“FCC”) exercises jurisdiction over services and regulates interstate and international communications in all 50 states, the District of Columbia and U.S territories. As an independent U.S. government agency overseen by Congress, the FCC is the United States' primary authority for communications laws, regulation and technological innovation.

   

We maintain Certificates of Public Convenience and Necessity in all 50 states, which enable us to provide services within each state. We are therefore subject to regulation from the Public Utility Commissions in each state.

 

 
6

Table of Contents

 

Intellectual Properties

 

In addition to other methods of protecting our proprietary technology, know-how and show-how as well as trade secrets, we pursue a policy of seeking patent protection, both in the US and abroad, for our proprietary technologies including those in Biox™ and MobiCare® products. Moreover, trademarks have been registered for the names “Vaso”, “Vasomedical”, “VasoGlobal”, “VasoSolutions”, “VasoHealthcare”, “ARCS”, and “MobiCare”.

 

Through our China-based subsidiaries, we own thirty-seven invention and utility patents in China that expire at various times through 2041, as well as sixteen software copyright certificates in China related to proprietary technologies in physiological data acquisition, analysis and reporting.  We also maintain five registered trademarks in China for our products.

 

Through our NetWolves subsidiary we hold a patent for Secure and Remote Monitoring Management (“SRM”) and we hold trademarks “NetWolves”, “SRM”, and “Wolfpac”.

 

There can be no assurance that our patents will not be violated or that any issued patents will provide protection that has commercial significance.  As with any patented technology, litigation could be necessary to protect our patent position.  Such litigation can be costly and time-consuming, and there can be no assurance that we will be successful.

 

Employees

 

As of December 31, 2022, we employed 272 full-time persons, of which 14 are employed through our facility in Plainview, New York; 85 through VasoHealthcare; 5 through VasoHealthcare IT; 111 through our NetWolves operations; and 57 in our China operations.  None of our employees are represented by a labor union.  We believe that our employee relations are good.

 

The Company also uses several part-time employees and consultants from time to time for various purposes.

 

Manufacturing

 

The Company conducts manufacturing activities primarily through its Biox facilities in China, while maintaining certain manufacturing capability in the Plainview, NY location to satisfy certain domestic and international needs for the EECP® systems.  The Biox facilities manufacture ambulatory monitoring devices and other medical devices.

 

All manufacturing operations are conducted under the cGMP requirements, as set forth in the FDA Quality System Regulation, as well as ISO 13485 (Medical device – Quality management systems – Requirement for regulatory purpose), an internationally agreed standard that sets out the requirements for a quality management system specific to the medical devices industry.  We are also certified to conform to full quality assurance system requirements of the EU Medical Device Directive (MDD 93/42/EEC Annex II) and can apply CE marking to all of our current product models.  Lastly, we are certified to comply with the requirements of the Brazilian Agência Nacional de Vigilncia Sanitária (ANVISA).  All these regulations and standards subject us to inspections to verify compliance and require us to maintain documentation and controls for the manufacturing and quality activities.

 

We believe our manufacturing capacity and warehouse facility are adequate to meet the current and immediately foreseeable future demand for the production of our medical devices.  We believe our suppliers of the other medical devices we distribute or represent are capable of meeting our demand for the foreseeable future. 

 

ITEM 1A - RISK FACTORS

 

You should carefully consider the risks and uncertainties described below, together with the information included elsewhere in this Report on Form 10K. The risks and uncertainties described below are those we have identified as material, but are not the only risks and uncertainties facing us. Our business is also subject to general risks and uncertainties that affect many other companies, such as market conditions, geopolitical events, changes in laws or accounting rules, fluctuation in interest rates, terrorism, wars or conflicts, major health concerns, natural disasters or other disruptions of economic or business conditions, including the possibility of a downturn in the U.S. economy and continued effects of the COVID-19 pandemic. Additional risks and uncertainties not currently known to us or that we currently believe are immaterial also may impair our business, including our results of operations, liquidity and financial position.

 

 
7

Table of Contents

 

Financial Risks

 

Achieving profitable operations is dependent on several factors

 

Our ability to sustain profitability is dependent on many factors, primarily being the sufficient and timely generation of cash, as well as attaining and maintaining profitability in our IT and equipment segments, as well as the success of our other strategic initiatives.

  

Risks Related to the COVID-19 Pandemic

 

The impact of the COVID-19 pandemic on our markets and financial condition is difficult to predict and manage.

 

The pandemic has adversely affected, and may continue to adversely affect, certain elements of our business, primarily the initial shrinkage, and subsequent recovery, of our customer base in our IT segment as well as the overall effect of China’s prior lockdown practice on its economy.  The COVID-19 pandemic has caused us to modify our business practices, and we may take further actions as required by government authorities, our customers or as determined to be in the best interests of our employees, customers and business partners. There is no certainty that these measures will be sufficient to mitigate the risks posed by the virus and our ability to execute our business plans could be impacted. The magnitude and duration of the disruption and resulting decline in business activity remain uncertain.

 

Risks Related to Our Business

 

We currently derive a significant amount of our revenue and operating income from our agreement with GEHC.

 

On May 19, 2010, we signed a sales representation agreement with GEHC.  Under the GEHC Agreement, we have been appointed GEHC’s exclusive representative for certain GEHC diagnostic imaging products to specific market segments in the 48 contiguous states of the United States and the District of Columbia.  The GEHC Agreement had an initial term of three years commencing July 1, 2010 and has subsequently been extended in 2012, 2014, 2017 and 2021, with the current term through December 31, 2026, subject to GEHC’s right to terminate earlier without cause under certain conditions.

 

A significant amount of our revenue and operating income arise from activities under this agreement.  Moreover, our performance and growth in the professional sales service segment depends partially on the territories, customer accounts and product modalities assigned to us by GEHC, as well as factors beyond our control such as product pricing, availability and delivery schedule, and thus relies on our ability to demonstrate our added value as a channel partner, and on maintaining a positive relationship with GEHC.  There is no assurance that the agreement will not be terminated prior to its expiration pursuant to its termination provisions or will be extended beyond the current expiration date.  Should GEHC terminate the agreement, it would have a material adverse effect on our financial condition and results of operations. 

 

We face competition from other companies and technologies.

 

In all segments of our business we compete with other companies that market technologies, products and services in the global marketplace.  We do not know whether these companies, or other potential competitors who may succeed in developing technologies, products or services that are more efficient or effective than those offered by us, and that would render our technology and existing products obsolete or non-competitive. Potential new competitors may also have substantially greater financial, manufacturing and marketing resources than those possessed by us. In addition, other technologies or products may be developed that have an entirely different approach or means of accomplishing the intended purpose of our products. Accordingly, the life cycles of our products are difficult to estimate. To compete successfully, we must keep pace with technological advancements, respond to evolving consumer requirements and achieve market acceptance.

 

 
8

Table of Contents

 

We depend on management and other key personnel.

 

We are dependent on a limited number of key management and technical personnel.  The loss of one or more of our key employees may harm our business if we are unable to identify other individuals to provide us with similar services.  We do not maintain “key person” insurance on any of our employees.  In addition, our success depends upon our ability to attract and retain additional highly qualified management, sales, IT, manufacturing and research and development personnel in our various operations.  The competition for IT personnel is intense.

 

We may not continue to receive necessary clearances or approvals from the US FDA or foreign authorities for our medical devices, which could hinder our ability to market and sell certain products in the relevant markets.

 

If we modify our medical devices and the modifications significantly affect safety or effectiveness, or if we make a change to the intended use, we will be required to submit a new premarket notification (510(k)) or premarket approval (PMA) application to the FDA. We would not be able to market the modified device in the U.S. until the FDA issues a clearance for the 510(k).

 

If we offer new products that require 510(k) clearance or a PMA, we will not be able to commercially distribute those products in the U.S. until we receive such clearance or approval.  Regulatory agency approval or clearance for a product may not be received or may entail limitations on the device’s indications for use that could limit the potential market for the product. Delays in receipt of, or failure to obtain or maintain, regulatory clearances and approvals, could delay or prevent our ability to market or distribute our products. Such delays could have a material adverse effect on our equipment business.

 

There are similar medical device regulations or requirements in China, Europe, and other foreign markets where we sell our products.  Failure to comply with these regulations and requirements could have a material adverse effect on our equipment business.

 

If we are unable to comply with applicable governmental regulations, we may not be able to continue certain of our operations.

 

As a reseller of telecommunication services and network solutions provider, our products and services are subject to federal, state and local regulations. These regulations govern, in part, our rates and the way we conduct our business, including the requirement to offer telecommunications services pursuant to nondiscriminatory rates, terms, and conditions, the obligation to safeguard the confidentiality of customer proprietary network information, as well as the obligation to maintain specialized records and file reports with the Federal Communications Commission and state regulatory authorities. While we believe we are in compliance with laws and regulations in jurisdictions where we do business, we must continue to monitor and assess our compliance.

 

We also must comply with current Good Manufacturing Practice requirements as set forth in the Quality System Regulation to receive US FDA approval to market new products and to continue to market current products. Most states also have similar regulatory and enforcement authority for medical devices.

 

Our operations in China are also subject to the laws and regulations of the People’s Republic of China with which we must be in compliance in order to conduct these operations.

 

We are subject to various federal, state and local laws targeting fraud and abuse in the healthcare industry, including anti-kickback and false claims laws.

 

 
9

Table of Contents

 

We cannot predict the nature of any future laws, regulations, interpretations, or applications, nor can we predict what effect additional governmental regulations or administrative orders, either domestically or internationally, when and if promulgated, would have on our business in the future. We may be slow to adapt, or we may never adapt to changes in existing requirements or adoption of new requirements or policies. We may incur significant costs to comply with laws and regulations in the future or compliance with laws or regulations may create an unsustainable burden on our business.

 

We have foreign operations and are subject to the associated risks of doing business in foreign countries.

 

The Company continues to have operations in China. Operating internationally involves additional risks relating to such things as currency exchange rates, different legal and regulatory environments, political, economic risks relating to the stability or predictability of foreign governments, differences in the manner in which different cultures do business, difficulties in staffing and managing foreign operations, differences in financial reporting, operating difficulties, and other factors. The occurrence of any of these risks, if severe enough, could have an adverse effect on the consolidated financial position, results of operations and cash flows of the Company.

 

Commercial law is still developing in China and there are limited legal precedents to follow in commercial transactions.  There are many tax jurisdictions each of which may have changing tax laws. Applicable taxes include value added taxes (“VAT”), enterprise income tax (“EIT”), and social (payroll) taxes.  Regulations are often unclear.  Tax declarations (reports) are subject to review and taxing authorities may impose fines, penalties and interest.  These facts create risks for our operations in China. 

 

We depend on several suppliers for the supply of certain products.

 

As a GEHC channel partner, we could be negatively impacted by interruptions or delays to equipment installations, production and quality issues, and any customer concerns related to GEHC.  Delivery of GEHC equipment may be negatively impacted due to the current supply chain issues especially as it impacts availability of computer chips.  With respect to our proprietary medical products we now manufacture our own products primarily through our China based facilities, and we depend on certain independent suppliers for parts, components and certain finished goods.   

 

We may not have adequate intellectual property protection.

 

Our patents and proprietary technology may not be able to prevent competition by others. The validity and breadth of claims in technology patents involve complex legal and factual questions. Future patent applications may not be issued, the scope of any patent protection may not exclude competitors, and our patents may not provide competitive advantages to us. Our patents may be found to be invalid and other companies may claim rights in or ownership of the patents and other proprietary rights held or licensed by us. Also, our existing patents may not cover products that we develop in the future. Moreover, when our patents expire, the inventions will enter the public domain. There can be no assurance that our patents will not be violated or that any issued patents will provide protection that has commercial significance. Litigation may be necessary to protect our patent position. Such litigation may be costly and time-consuming, and there can be no assurance that we will be successful in such litigation.

 

The loss or violation of certain of our patents and trademarks could have a material adverse effect upon our business.

 

Since patent applications in the United States are maintained in secrecy until such patent applications are issued, our current product development may infringe patents that may be issued to others. If our products were found to infringe patents held by competitors, we may have to modify our products to avoid infringement, and it is possible that our modified products would not be commercially successful.

 

 
10

Table of Contents

 

Risks Related to Our Industries

 

Our growth could suffer if the markets into which we sell products decline, do not grow as anticipated or experience cyclicality.

 

Our growth depends in part on the growth of the IT and healthcare markets which we serve. In our professional sales services segment, our quarterly sales and profits depend significantly on the volume and timing of delivery of the underlying equipment of the orders we booked, and the delivery of such products is difficult to forecast since it is largely dependent on GEHC.  Product demand is dependent upon the customer’s capital spending budget as well as government funding policies, and matters of public policy as well as product cycles and economic downturns that can affect the spending decisions of these entities. These factors could adversely affect our growth, financial position, and results of operations.

 

Technological change is difficult to predict and to manage.

 

We face the challenges that are typically faced by companies in the IT and medical device fields. Our products and services may require substantial development efforts and compliance with governmental clearance or approval requirements. We may encounter unforeseen technological or scientific problems that force abandonment or substantial change in the development of a specific product or process.

 

We are subject to product liability claims and product recalls that may not be covered by insurance.

 

The nature of our manufacturing operations exposes us to risks of product liability claims and product recalls. Medical devices as complex as ours frequently experience errors or failures, especially when first introduced or when new versions are released.

 

We currently maintain product liability insurance at $6,000,000 per occurrence and in the aggregate.  Our product liability insurance may not be adequate. In the future, insurance coverage may not be available on commercially reasonable terms, or at all. In addition, product liability claims or product recalls could damage our reputation even if we have adequate insurance coverage.

  

Risks Related to our Securities

 

The application of the “penny stock” rules could adversely affect the market price of our common stock and increase your transaction costs to sell those shares.

 

As long as the trading price of our common shares is below $5 per share, the open-market trading of our common shares will be subject to the “penny stock” rules.  The “penny stock” rules impose additional sales practice requirements on broker-dealers who sell securities to persons other than established customers and accredited investors (generally those with assets in excess of $1,000,000 or annual income exceeding $200,000 or $300,000 together with their spouse).  For transactions covered by these rules, the broker-dealer must make a special suitability determination for the purchase of securities and have received the purchaser’s written consent to the transaction before the purchase.  Additionally, for any transaction involving a penny stock, unless exempt, the broker-dealer must deliver, before the transaction, a disclosure schedule prescribed by the Securities and Exchange Commission relating to the penny stock market.  The broker-dealer also must disclose the commissions payable to both the broker-dealer and the registered representative and current quotations for the securities.  Finally, monthly statements must be sent disclosing recent price information on the limited market in penny stocks.  These additional burdens imposed on broker-dealers restrict the ability and decrease the willingness of broker-dealers to sell our common shares, which we believe results in decreased liquidity for our common shares as well as increased transaction costs for sales and purchases of our common shares as compared to other securities.

 

Our common stock is subject to price volatility.

 

The market price of our common stock historically has been and may continue to be highly volatile.  Our stock price could be subject to wide fluctuations in response to various factors beyond our control, including, but not limited to:

 

 

·

actual or anticipated fluctuations in our operating results;

 

·

overall market fluctuations and domestic and worldwide economic conditions;

 

·

medical reimbursement;

 

 
11

Table of Contents

 

 

·

announcements of technological innovations, new products or pricing by our competitors;

 

·

the timing of patent and regulatory approvals;

 

·

the timing and extent of technological advancements;

 

·

the sales of our common stock by affiliates or other shareholders with large holdings; and

 

·

other factors described in the “Risk Factors” and elsewhere in this Report.

 

Our future operating results may fall below the expectations of securities industry analysts or investors. Any such shortfall could result in a significant decline in the market price of our common stock. In addition, the stock market has experienced significant price and volume fluctuations that have affected the market price of our stock and that often have been unrelated to the operating performance of such companies. These broad market fluctuations may directly influence the market price of our common stock.

 

We do not intend to pay dividends in the foreseeable future.

 

We currently do not intend to pay any cash dividends on our common stock in the foreseeable future.

 

Additional Information

 

We are subject to the reporting requirements under the Securities Exchange Act of 1934 and are required to file reports and information with the Securities and Exchange Commission (SEC), including reports on the following forms: annual report on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K, and amendments to those reports files or furnished pursuant to Section 13(a) or 15(d) of the Securities Act of 1934.

 

ITEM 2 – PROPERTIES

 

The Company leases its headquarters at an 8,700 square foot facility at 137 Commercial Street, Plainview, New York 11803, under a lease with a term that expires on September 30, 2025 and with a base annual rental of approximately $78,000. The Company’s NetWolves unit leases a 16,200 square foot facility in Tampa, Florida, under a lease expiring in June 2024 with an annual rental of approximately $194,000. VHC-IT leases a flexible space, 1,500 square foot facility in Nashville, Tennessee with an annual cost of approximately $32,000. The Nashville lease expired on January 31, 2023 and is currently rented on a month-to-month basis. We believe that our current facilities are adequate for foreseeable current and future needs.

  

We lease our office, engineering and production facilities in China.  Specifically, we lease approximately 14,700 square feet of space in Wuxi, China under leases expiring in August 2023, September 2023, and December 2023 at an aggregate annual cost of approximately $71,000.  Such leases are renewable upon expiration.

 

 
12

Table of Contents

 

PART II

 

ITEM 5 – MARKET FOR REGISTRANT’S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES

 

Our common stock currently trades on the OTC Market (OTCQB) under the symbol VASO.  The number of record holders of common stock as of March 24, 2023, was approximately 900, which does not include approximately 8,500 beneficial owners of shares held in the name of brokers or other nominees.  The table below sets forth the range of high and low trade prices of the common stock for the fiscal periods specified.

 

 

 

Year ended December 31, 2022

 

 

Year ended December 31, 2021 

 

 

 

High

 

 

Low

 

 

High

 

 

Low

 

First quarter

 

$0.09

 

 

$0.05

 

 

$0.16

 

 

$0.08

 

Second quarter

 

$0.11

 

 

$0.07

 

 

$0.12

 

 

$0.05

 

Third quarter

 

$0.12

 

 

$0.09

 

 

$0.07

 

 

$0.05

 

Fourth quarter

 

$0.22

 

 

$0.11

 

 

$0.08

 

 

$0.04

 

 

The last bid price of the Company’s common stock on March 24, 2023 was $0.23 per share.

 

Dividend Policy

 

We have never paid any cash dividends on our common stock and currently do not intend to pay cash dividends in the foreseeable future.

 

ITEM 7 – MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.

 

This Management’s Discussion and Analysis of Financial Condition and Results of Operations contains descriptions of our expectations regarding future trends affecting our business. These forward looking statements and other forward-looking statements made elsewhere in this document are made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Please read the section titled “Risk Factors” in “Item One – Business” to review certain conditions, among others, which we believe could cause results to differ materially from those contemplated by the forward-looking statements.

 

Except for historical information contained in this report, the matters discussed are forward-looking statements that involve risks and uncertainties. When used in this report, words such as “anticipates”, “believes”, “could”, “estimates”, “expects”, “may”, “plans”, “potential” and “intends” and similar expressions, as they relate to the Company or its management, identify forward-looking statements. Such forward-looking statements are based on the beliefs of the Company’s management, as well as assumptions made by and information currently available to the Company’s management. Among the factors that could cause actual results to differ materially are the following: the effect of business and economic conditions, including the COVID-19 pandemic; the effect of the dramatic changes taking place in IT and healthcare; continuation of the GEHC agreement; the impact of competitive technology and products and their pricing; medical insurance reimbursement policies; unexpected manufacturing or supplier problems; unforeseen difficulties and delays in the conduct of product development programs; the actions of regulatory authorities and third-party payers in the United States and overseas;  and the risk factors reported from time to time in the Company’s SEC reports.  The Company undertakes no obligation to update forward-looking statements as a result of future events or developments.

 

The following discussion should be read in conjunction with the financial statements and notes thereto included in this Annual Report on Form 10-K.

 

 
13

Table of Contents

 

General Overview

 

COVID-19 pandemic

 

The COVID-19 pandemic has had a significant impact on economies of the United States and China, and it is possible that some negative impact to the Company’s financial condition and results of operations may continue.  At this time, we cannot reasonably estimate what the total impact may be. The pandemic has resulted in workforce and travel restrictions and created business disruptions in supply chain, production and demand across many business sectors. We have experienced negative impact in the recurring revenue business in our IT segment as some of our customers have been adversely affected by the shutdown, and new business in this segment appears to be slower as well.  In addition, revenues in our China operations have been adversely affected by its government’s lockdown policies, which have only recently been reversed.  

 

We have taken significant steps in our efforts to protect our workforce and our clients. Most of our employees have worked at least partially remotely and we have reopened our work sites consistent with the guidelines promulgated by the CDC and respective state governments. In addition, the Company in 2020 received a $3.6 million loan under the Paycheck Protection Program of the CARES Act (the “PPP loan”). This loan was used to principally cover our payroll costs for a period of time as specified by the rules, thereby allowing us to maintain our workforce and continue to provide services and solutions to our clients.  In June 2021, the loan, as well as accrued interest, was forgiven in its entirety by the Small Business Administration.

 

Our Business Segments

 

Vaso Corporation (formerly Vasomedical, Inc.) (“Vaso”) was incorporated in Delaware in July 1987.  We principally operate in three distinct business segments in the healthcare equipment and information technology industries.  We manage and evaluate our operations, and report our financial results, through these three business segments.

 

 

·

IT segment, operating through a wholly-owned subsidiary VasoTechnology, Inc., primarily focuses on healthcare IT and managed network technology services;

 

 

 

 

·

Professional sales service segment, operating through a wholly-owned subsidiary Vaso Diagnostics, Inc. d/b/a VasoHealthcare, primarily focuses on the sale of healthcare capital equipment for GE HealthCare (GEHC) into the health provider middle market; and

 

 

 

 

·

Equipment segment, primarily focuses on the design, manufacture, sale and service of proprietary medical devices and software, operating through a wholly-owned subsidiary VasoMedical, Inc., which in turn operates through Vasomedical Solutions, Inc. for domestic business and Vasomedical Global Corp. for international business, respectively.

 

VasoTechnology

 

VasoTechnology, Inc. was formed in May 2015, at the time the Company acquired all of the assets of NetWolves, LLC and its affiliates, including the membership interests in NetWolves Network Services LLC (collectively, “NetWolves”).  It currently consists of a managed network and security service division (NetWolves) and a healthcare IT application VAR (value added reseller) division (VasoHealthcare IT).  Its current offering includes:

 

 

·

Managed diagnostic imaging applications (channel partner of select vendors of healthcare IT products).

 

·

Managed network infrastructure (routers, switches and other core equipment).

 

·

Managed network transport (FCC licensed carrier reselling 175+ facility partners).

 

·

Managed security services.

 

VasoTechnology uses a combination of proprietary technology, methodology and best-in-class third-party applications to deliver its value proposition.

 

 
14

Table of Contents

 

VasoHealthcare

 

VasoHealthcare commenced operations in 2010, in conjunction with the Company’s execution of its exclusive sales representation agreement with GEHC, which at the time was the healthcare business division of the General Electric Company (“GE”), to further the sale of certain medical capital equipment in certain domestic market segments.  Its current offering consists of:

 

 

·

GEHC diagnostic imaging equipment and ultrasound systems.

 

·

GEHC service agreements for the above equipment.

 

·

GEHC training services for use of the above equipment.

 

·

GEHC and third-party financial services for the above equipment.

 

VasoHealthcare has built a team of over 75 highly experienced sales professionals who utilize highly focused sales management and analytic tools to manage the complete sales process and to increase market penetration.

 

VasoMedical

 

The proprietary medical equipment business under VasoMedical traces back to 1995 when the Company began the proprietary Enhanced External Counterpulsation (EECP®) technology in the United States and has since diversified to include other medical hardware and software.  Vasomedical Global was formed in 2011 to combine and coordinate the various international operations including design, development, manufacturing, and sales of medical devices and software, while domestic activities are conducted under Vasomedical Solutions.  These devices and software primarily consist of cardiovascular diagnostic and therapeutic applications, including:

 

 

·

Biox™ series Holter monitors and ambulatory blood pressure recorders.

 

·

ARCS® series analysis, reporting and communication software for ECG and blood pressure signals, including cloud-based software and algorithm subscription services.

 

·

MobiCare® multi-parameter wireless vital-sign monitoring system.

 

·

EECP® therapy systems for non-invasive, outpatient treatment of ischemic heart disease.

 

This segment uses its extensive in-house knowledge for cardiovascular devices and software coupled with its engineering resources to cost effectively create and market its proprietary technology. It sells and services its products to customers in the U.S. and China directly and sells and/or services its products in the international market mainly through independent distributors.

 

Strategic Plan and Objectives

 

Our short- and long-term plans for the growth of the Company and to increase stockholder value are:

 

 

·

Continue to effectively control operating costs in the current inflationary environment.

 

·

Continue to expand our product and service offerings as well as market penetration in all of our business segments.

 

·

Maintain and improve business performance in our professional sales service segment by increasing market penetration of the GEHC product modalities we represent, and possibly building new teams to represent other vendors.

 

·

Maintain and grow our equipment business by increasing efficiency and exploring new revenue models.

 

·

Continue to seek accretive partnership opportunities.

 

·

Explore options in capital markets for our stock.

 

 
15

Table of Contents

 

Results of Operations – For the Years Ended December 31, 2022 and 2021

 

Total revenues increased by $4,438,000, or 5.9%, to $80,017,000 in the year ended December 31, 2022, from $75,579,000 in the year ended December 31, 2021.  We reported net income of $11,873,000 and $6,100,000 for the years ended December 31, 2022 and 2021, respectively, an improvement of $5,773,000.  The increase in net income was primarily due to higher gross profit and the income tax benefit generated through partial release of the deferred tax asset valuation allowance, partially offset by higher operating costs and forgiveness of the PPP loan in 2021.  Our net income was $0.07 and $0.04 per basic and diluted common share for the years ended December 31, 2022 and 2021, respectively.

 

Revenues

 

Revenue in the IT segment was $40,100,000 for the year ended December 31, 2022 as compared to $42,916,000 for the prior year, a decrease of $2,816,000, or 6.6%, of which $2,028,000 was attributable to a decline in NetWolves revenues and $788,000 by a decrease in VHC-IT revenues.  

 

Commission revenues in the professional sales service segment increased by $7,903,000, or 26.8%, to $37,344,000 in the year ended December 31, 2022, as compared to $29,441,000 in the year ended December 31, 2021.  The increase was primarily due to higher volume of GEHC equipment delivered in 2022 coupled with a higher blended commission rate for equipment delivered in 2022.  As discussed in Note B to the financial statements, the Company defers recognition of commission revenue until the underlying equipment is delivered.  As of December 31, 2022, the Company recorded on its consolidated balance sheet deferred commission revenue of $30,794,000 for this segment (of which $15,660,000 is long-term), an increase of $5,839,000, or 23.3%, compared to $24,955,000 of deferred commission revenue at December 31, 2021 (of which $8,465,000 was long-term).  The increase in deferred revenue is due principally to higher total orders booked during the year, partially offset by the increase in equipment deliveries over the same period.

 

Revenue in our equipment segment decreased 20.1% to $2,573,000 for the year ended December 31, 2022 from $3,222,000 for the year ended December 31, 2021, as a result of lower equipment sales in our China operations as affected by the pandemic lockdowns in the country and the effect of 2022 foreign exchange rate fluctuations, offset by a $16,000 increase in our US operations due to higher ARCS®-cloud software-as-a-service revenues.   

 

Gross Profit

 

The Company recorded gross profit of $48,481,000, or 60.6% of revenue, for the year ended December 31, 2022, compared to $43,133,000, or 57.1% of revenue, for the year ended December 31, 2021.  The increase of $5,348,000, or 12.4%, was due primarily to a $6,382,000 increase in the professional sales service segment due to higher revenues, partially offset by decreases of $589,000 and $445,000 in the equipment and IT segments, respectively, as a result of lower revenues in both segments and lower gross margin in the equipment segment. 

 

IT segment gross profit decreased to $16,229,000, or 40% of segment revenues, for the year ended December 31, 2022, as compared to $16,674,000, or 39% of segment revenues in the prior year, a decrease of $445,000, of which $885,000 was attributable to NetWolves due to lower revenues, offset by $440,000 higher gross profit at VHC-IT, resulting from improved gross margin.

 

Professional sales service segment gross profit was $30,288,000, or 81.1% of the segment revenues, for the year ended December 31, 2022, an increase of $6,382,000, or 26.7%, from segment gross profit of $23,906,000, or 81.2% of the segment revenue, for the year ended December 31, 2021.  The increase in gross profit was due primarily to the increase in the segment revenue as a result of higher equipment delivery volume and a higher blended commission rate in 2022.  Cost of commissions increased by $1,521,000, or 27.5%, to $7,056,000 for the year ended December 31, 2022, as compared to cost of commissions of $5,535,000 in 2021.  The increase is due primarily to the increase in the segment revenue as gross profit margin remained little changed year over year.  Cost of commissions reflects commission expense associated with certain recognized commission revenues.  Commission expense associated with deferred revenue is recorded as deferred commission expense until the related commission revenue is earned. 

 

 
16

Table of Contents

 

Equipment segment gross profit decreased by $589,000, or 23.1%, to $1,964,000, or 76.3% of equipment segment revenues, for the year ended December 31, 2022, compared to $2,553,000, or 79.2% of equipment segment revenues, for the year ended December 31, 2021, due to lower segment revenue as well as lower gross profit margin in our China operations.  Equipment segment gross profits are dependent on a number of factors including the mix of products sold, their respective models and average selling prices, the ongoing costs of training, maintenance and servicing, as well as certain fixed period costs, including facilities, payroll and insurance.

 

Operating Income

 

Operating income was $7,033,000 for the year ended December 31, 2022 compared to operating income of $2,819,000 for the year ended December 31, 2021, an increase of $4,214,000, or 149%.  The improvement was primarily attributable to the increase in operating income in the professional sales service segment to $10,099,000 for the year ended December 31, 2022 from $5,918,000 for the year ended December 31, 2021, due to higher gross profit, offset by higher operating expenses, and by a $442,000 improvement in the IT segment, which lowered its operating loss to $1,620,000 for the year ended December 31, 2022 from $2,062,000 for the year ended December 31, 2021, as a result primarily of lower operating expenses.  Offsetting these improvements was a $212,000 increase in operating loss in the equipment segment to $180,000 for the year ended December 31, 2022 from operating income of $32,000 in the prior year resulting mainly from lower gross profit, partially offset by lower SG&A expenses, and a $197,000 increase in corporate expenses to $1,266,000 for the year ended December 31, 2022 from $1,069,000 in the prior year, mainly due to increases in insurance costs and director fees.

 

Selling, general and administrative (SG&A) expenses for the years ended December 31, 2022 and 2021 were $40,843,000, or 51.0% of revenues, and $38,593,000, or 51.1% of revenues, respectively, reflecting an increase of $2,250,000 or 5.8%. The increase in SG&A expenditures in the year ended December 31, 2022 resulted primarily from a $2,202,000 increase in the professional sales service segment attributable mainly to higher sales personnel-related and travel costs; a $302,000 increase in the IT segment due to higher personnel and travel costs; a $47,000 decrease in the equipment segment due mainly to lower personnel costs in our China operations, and by a $197,000 increase in corporate expenses reflecting higher insurance costs and director fees.

 

Research and development (R&D) expenses of $605,000, or 1% of revenues, for the year ended December 31, 2022 decreased by $1,116,000, or 65%, from $1,721,000, or 2% of revenues, for the year ended December 31, 2021. The decrease is primarily attributable to a one-time write-off of software development costs in our NetWolves operations in 2021.

 

Adjusted EBITDA

 

We define Adjusted EBITDA (earnings before interest, taxes, depreciation and amortization), which is a non-GAAP financial measure, as net (loss) income, plus net interest expense (income), tax expense, depreciation and amortization, and non-cash expenses for share-based compensation.  Adjusted EBITDA is a metric that is used by the investment community for comparative and valuation purposes.  We disclose this metric in order to support and facilitate the dialogue with research analysts and investors.

 

Adjusted EBITDA is not a measure of financial performance under accounting principles generally accepted in the United States (“GAAP”) and should not be considered a substitute for operating income, which we consider to be the most directly comparable GAAP measure. Adjusted EBITDA has limitations as an analytical tool, and when assessing our operating performance, you should not consider Adjusted EBITDA in isolation, or as a substitute for net income or other consolidated income statement data prepared in accordance with GAAP. Other companies may calculate Adjusted EBITDA differently than we do, limiting its usefulness as a comparative measure.

 

A reconciliation of net income to Adjusted EBITDA is set forth below:

 

 

 

(in thousands)

 

 

 

Year ended December 31,

 

 

 

2022

 

 

2021

 

 

 

 

 

 

 

 

Net income

 

$11,873

 

 

$6,100

 

Interest expense (income), net

 

 

(85)

 

 

301

 

Income tax (benefit) expense

 

 

(4,743)

 

 

151

 

Depreciation and amortization

 

 

1,923

 

 

 

3,840

 

Share-based compensation

 

 

35

 

 

 

31

 

Adjusted EBITDA

 

$9,003

 

 

$10,423

 

 

 
17

Table of Contents

 

Adjusted EBITDA decreased by $1,420,000, to $9,003,000 in the year ended December 31, 2022, from $10,423,000 in the year ended December 31, 2021.  The decrease was primarily attributable to the lower depreciation and amortization and the change from income tax expense to income tax benefit, partially offset by higher net income and the change from net interest expense to net interest income, as compared to the prior year.   Net income increased primarily due to higher revenue, gross profit and income tax benefit in 2022, partially offset by $3,646,000 gain on forgiveness of PPP loan and interest in 2021.

  

Other Income (Expense), Net

 

Other income (expense), net for the years ended December 31, 2022 and 2021, was $97,000 and $3,432,000, respectively, a decrease in net other income of $3,335,000.  The decrease was due primarily to the gain on forgiveness of the PPP loan and interest of $3,646,000 in 2021, partially offset by $268,000 lower interest expense in 2022 due to reduced debt and finance lease obligations.

  

Income Tax (Expense) Benefit

 

During the year ended December 31, 2022, we recorded an income tax benefit of $4,743,000, as compared to income tax expense of $151,000 in the year ended December 31, 2021.  The Company utilized $7,754,000 and $4,373,000 in net operating loss carryforwards for the years ended December 31, 2022 and 2021, respectively.  The change to income tax benefit in 2022 arose primarily from the partial release of the deferred tax asset valuation allowance in 2022, due to estimated future taxable income.  The Company has net operating loss carryforwards of approximately $31 million at December 31, 2022.

 

Liquidity and Capital Resources

 

Cash and Cash Flow – For the year ended December 31, 2022

 

We have financed our operations and investment activities from working capital.  At December 31, 2022, we had cash and cash equivalents and short-term investments of $20,325,000 and working capital of $10,292,000.  $11,890,000 in negative working capital at December 31, 2022 is attributable to the net balance of deferred commission expense and deferred revenue.  These are non-cash expense and revenue items and have no impact on future cash flows.  At March 24, 2023 the Company’s cash and cash equivalents and short-term investments were approximately $20.4 million.

 

Cash provided by operating activities was $14,416,000 during the year ended December 31, 2022, which consisted of net income after non-cash adjustments of $9,260,000 and changes in operating assets and liabilities of $5,156,000. The changes in the account balances primarily reflect increases in deferred revenue, accrued expenses, and accrued commissions of $5,838,000, $1,392,000, and $1,094,000, respectively; partially offsetting these changes was an increase in other assets of $2,422,000 and a decrease in accounts payable of $521,000.

 

Cash used in investing activities during the year ended December 31, 2022 was $8,417,000, consisting of $8,000,000 in purchases of short term investments and $566,000 in purchases of equipment and software, offset by $149,000 in redemption of short-term investments.

 

Cash used in financing activities during the year ended December 31, 2022 was $230,000 in payments of notes and finance leases.

 

 
18

Table of Contents

 

Liquidity

 

The Company expects to generate sufficient cash flow from operations to satisfy its obligations at least for the next twelve months. 

 

Off-Balance Sheet Arrangements

 

We do not participate in transactions that generate relationships with unconsolidated entities or financial partnerships, such as entities often referred to as structured finance or special purpose entities (SPES), which would have been established for the purpose of facilitating off-balance sheet arrangements or other contractually narrow or limited purposes.  As of December 31, 2022, we are not involved in any unconsolidated SPES or other off-balance sheet arrangements.

 

Effects of Inflation

 

We believe that inflation and changing prices over the past two years have not had a significant impact on our revenue or on our results of operations.

 

Critical Accounting Policies and Estimates

 

Note B of the Notes to Consolidated Financial Statements includes a summary of our significant accounting policies and methods used in the preparation of our financial statements. In preparing these financial statements, we have made our best estimates and judgments of certain amounts included in the financial statements, giving due consideration to materiality. The application of these accounting policies involves the exercise of judgment and use of assumptions as to future uncertainties and, as a result, actual results could differ from these estimates. Our critical accounting policies and estimates are as follows:

 

Allowance for Commission Adjustments

 

In our professional sale service segment, we bill a portion of commissions on the orders we booked in advance of delivery of the underlying equipment.  Such amounts are classified in our consolidated balance sheets in accounts receivable and deferred revenue, net of estimated commission adjustments.  Similarly, commissions payable to our sales force related to such billings are recorded as deferred commission expense, net of the impact of the estimated commission adjustments, when the associated deferred revenue is recorded.  The commission adjustments are based on estimates of future order cancellations, which is calculated based on historical cancellation rates and applicable credit policies.  

 

Valuation Allowance for Deferred Tax Assets

 

Deferred income taxes are recognized for temporary differences between financial statement and income tax bases of assets and liabilities and loss carry forwards for which income tax benefits are expected to be realized in future years. A valuation allowance is established, when necessary, to reduce deferred tax assets to the amount expected to be realized. In estimating future tax consequences, we generally consider all expected future events other than an enactment of changes in the tax laws or rates. Deferred tax assets are continually evaluated for realizability. To the extent our judgment regarding the realization of the deferred tax assets changes, an adjustment to the allowance is recorded, with an offsetting increase or decrease, as appropriate, in income tax expense. Such adjustments are recorded in the period in which our estimate as to the realizability of the assets changed that it is “more likely than not” that all of the deferred tax assets will be realized. The “more likely than not” standard is subjective and is based upon our estimate of a greater than 50% probability that the deferred tax asset will be realized.

 

Goodwill and Intangible Assets

 

Goodwill represents the excess of cost over the fair value of net assets of businesses acquired. The Company accounts for goodwill under the guidance of the ASC Topic 350, “Intangibles: Goodwill and Other”. Goodwill acquired in a purchase business combination and determined to have an indefinite useful life is not amortized, but instead tested for impairment, at least annually, in accordance with this guidance. The recoverability of goodwill is subject to an annual impairment test or whenever an event occurs or circumstances change that would more likely than not result in an impairment. The impairment test is based on the estimated fair value of the underlying businesses and performed in the fourth quarter of each year.

 

Intangible assets consist of the value of customer contracts and relationships, patent and technology costs, and software. The cost of significant customer-related intangibles is amortized in proportion to estimated total related revenue; cost of other intangible assets is generally amortized on a straight-line basis over the asset's estimated economic life, which range from five to ten years. The Company capitalizes internal use software costs incurred during the application development stage. Costs related to preliminary project activities and post implementation activities are expensed as incurred. We evaluate whether events or circumstances have occurred that warrant a revision to the remaining useful lives of intangible assets. In cases where a revision is deemed appropriate, the remaining carrying amounts of the intangible assets are amortized over the revised remaining useful life.

 

Recently Issued Accounting Pronouncements

 

Note B of the Notes to Consolidated Financial Statements includes a description of the Company’s evaluation of recently issued accounting pronouncements.

 

ITEM 8 - FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA

 

The consolidated financial statements listed in the accompanying Index to Consolidated Financial Statements are filed as part of this report.

 

ITEM 9A - CONTROLS AND PROCEDURES

 

Report on Disclosure Controls and Procedures

 

Disclosure controls and procedures reporting as promulgated under the Exchange Act is defined as controls and procedures that are designed to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act are recorded, processed, summarized and reported within the time periods specified in the SEC rules and forms.  Disclosure controls and procedures include without limitation, controls and procedures designed to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is accumulated and communicated to our management, including our Chief Executive Officer (“CEO”) and Chief Financial Officer (“CFO”), or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.

 

 
19

Table of Contents

 

Our CEO and our CFO have evaluated the effectiveness of the design and operation of our disclosure controls and procedures as of December 31, 2022 and have concluded that the Company’s disclosure controls and procedures were effective.

 

Management’s Report on Internal Control over Financial Reporting

 

Management is responsible for establishing and maintaining adequate internal control over financial reporting for the Company as defined in Rule 13a-15(f) and 15d-15(f) of the Exchange Act. Internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial statements for external purposes in accordance with accounting principles generally accepted in the United States of America. Internal control involves maintaining records that accurately represent our business transactions, providing reasonable assurance that receipts and expenditures of company assets are made in accordance with management authorization, and providing reasonable assurance that unauthorized acquisition, use or disposition of company assets that could have a material effect on our financial statements would be detected or prevented on a timely basis.

 

Because of its inherent limitations, internal control over our financial statements is not intended to provide absolute guarantee that a misstatement can be detected or prevented in the statements.  Therefore, even those systems determined to be effective can provide only reasonable assurance with respect to financial statement preparation and presentation.  Also projections of any evaluation of effectiveness to future periods are subject to risk that controls may become inadequate because of changes in condition, or that the degree of compliance with the policies or procedures may deteriorate.

  

Management conducted an evaluation of the effectiveness of our internal control over financial reporting based on the framework in Internal Control – Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 COSO framework).  A material weakness is a deficiency, or combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of the Company’s annual or interim financial statements will not be prevented or detected on a timely basis.

 

Based on this evaluation and those criteria, the Company’s CEO and CFO concluded that the Company’s internal control over financial reporting were effective as of December 31, 2022.

 

This report does not include an attestation report of the Company’s Independent Registered Public Accounting Firm regarding internal control over financial reporting. Management’s report was not subject to attestation by the Company’s Independent Registered Public Accounting Firm pursuant to temporary rules of the Securities and Exchange Commission that permit the Company to provide only Management’s report in this Annual Report.

 

Changes in Internal Control over Financial Reporting

 

For the quarter ended December 31, 2022 there were no changes in our internal control over financial reporting that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

 

 
20

Table of Contents

 

ITEM 9B – OTHER INFORMATION

 

The Company held its Annual Meeting of Stockholders on November 15, 2022. At the meeting, the Company’s stockholders voted to approve the following proposals:

 

 

1)

The election of two directors in Class II to hold office until the 2025 Annual Meeting of Stockholders.

 

 

 

 

2)

The appointment of UHY LLP as our independent registered public accountants for the year ending December 31, 2022.

 

The following table presents the voting results on these proposals:

 

Approved Proposals

 

Stockholder votes cast

 

 

 

For

 

 

Withheld

 

 

Against

 

 

Abstain

 

Election of Directors

 

 

 

 

 

 

 

 

 

 

 

 

Behnam Movaseghi

 

 

98,413,490

 

 

 

4,739,834

 

 

 

 

 

 

 

Jane Moen

 

 

98,983,419

 

 

 

4,169,905

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Appointment of public accountants

 

 

129,365,135

 

 

 

 

 

 

 

3,192,285

 

 

 

91,592

 

 

 
21

Table of Contents

 

PART III

 

ITEM 10 – DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE

 

Directors of the Registrant

 

                As of March 24, 2023, the members of our Board of Directors are:

 

Name of Director

 

Age

 

Principal Occupation

 

Director Since

Joshua Markowitz (2)

 

67

 

Chairman of the Board and Director

 

June, 2015

David Lieberman

 

78

 

Vice Chairman of the Board and Director

 

February, 2011

Jun Ma

 

59

 

President, Chief Executive Officer and Director

 

June, 2007

Jane Moen

 

43

 

President, Vasohealthcare and Director

 

March, 2020

Behnam Movaseghi (1) (2)

 

69

 

Director

 

July, 2007

Edgar Rios (1)

 

70

 

Director

 

February, 2011

______________

(1)

Member of the Audit Committee

(2)

Member of the Compensation Committee

 

The following is a brief account of the business experience for at least the past five years of our directors:

 

Joshua Markowitz has been a director since June 2015, and was appointed Chairman of the Board of the Company in August 2016.  Mr. Markowitz has been a practicing attorney in the State of New Jersey for in excess of 30 years.  He is currently a senior partner in the New Jersey law firm of Markowitz O’Donnell, LLP.  Mr. Markowitz was the brother-in-law of Mr. Simon Srybnik (deceased), the former Chairman and director of the Company.

 

David Lieberman has been a director of the Company and the Vice Chairman of the Board, since February 2011. Mr. Lieberman has been a practicing attorney in the State of New York for more than 45 years, specializing in corporation and securities law. He is currently of counsel to the law firm of Ortoli Rosenstadt, LLP, which performs certain legal services for the Company and its subsidiaries.  Mr. Lieberman is a former Chairman of the Board of Herley Industries, Inc., which was sold in March, 2011.

 

Jun Ma, PhD, has been a director since June 2007 and was appointed President and Chief Executive Officer of the Company on October 16, 2008.   Dr. Ma has held various positions in academia and business, and prior to becoming President and CEO of the Company, had provided technology and business consulting services to several domestic and international companies in aerospace, automotive, biomedical, medical device, and other industries, including Kerns Manufacturing Corp. and Living Data Technology Corp., both of which are stockholders of our Company.  Dr. Ma received his PhD degree in mechanical engineering from Columbia University, MS degree in biomedical engineering from Shanghai University, and BS degree in precision machinery and instrumentation from University of Science and Technology of China.

 

Jane Moen has been a director since March 2020 and an executive officer of the Company since November 2022.  Ms. Moen has been President of the Company’s wholly-owned subsidiary Vaso Diagnostics, Inc. d/b/a VasoHealthcare since June 2018 following a remarkable career track record at VasoHealthcare, starting as an Account Manager at the inception of VasoHealthcare in April 2010 and being promoted to Regional Manager in January 2012, Director of Product Business Lines in July 2012 and Vice President of Sales in April 2016. Jane Moen has been in the medical sales industry for over 17 years, having had prior experience with Ledford Medical Sales, Vital Signs, Inc., Pfizer Inc. and Ecolab, Inc.

 

Behnam Movaseghi, CPA, has been a director since July 2007. Mr. Movaseghi has been treasurer of Kerns Manufacturing Corporation since 2000, and controller from 1990 to 2000. For approximately ten years prior thereto Mr. Movaseghi was a tax and financial consultant. Mr. Movaseghi is a Certified Public Accountant. 

 

 
22

Table of Contents

 

Edgar G. Rios has been a director of the Company since February 2011. Mr. Rios currently is President of Edgary Consultants, LLC. and was appointed a director in conjunction with the Company’s prior consulting agreement with Edgary Consultants, LLC. Most recently from 2008 thru the end of 2016, Mr. Rios was the Co-founder, CEO and Managing Member of SHD Oil & Gas LLC, an oil and gas exploration and development firm operating on the reservation of the Three Affiliate Tribes in North Dakota. Previously, Mr. Rios was a co-founder, Executive Vice President, General Counsel and Director of AmeriChoice Corporation from its inception in 1989 through its acquisition by UnitedHealthcare in 2002 and continued as a senior executive with United Healthcare through 2007. Prior to co-founding AmeriChoice, Mr. Rios was a senior executive with a number of businesses that provided technology services and non-technology products to government purchasers. Over the years, Mr. Rios also has been an investor, providing seed capital to various technology and nontechnology start-ups. Mr. Rios serves on the Board of Advisors of Columbia Law School. Mr. Rios also serves as a member of the Board of Trustees of Meharry Medical School and the Brookings Institution in Washington; and as a director of the An-Bryce Foundation and Los Padres Foundation in Virginia. Mr. Rios holds a J.D. from Columbia University Law School and an A.B. from Princeton University.

 

Committees of the Board of Directors

 

Audit Committee and Audit Committee Financial Expert

 

The Board has a standing Audit Committee.  The Board has affirmatively determined that each director who serves on the Audit Committee is independent, as the term is defined by applicable Securities and Exchange Commission (“SEC”) rules.  During the year ended December 31, 2022, the Audit Committee consisted of Edgar Rios, committee chair, and Behnam Movaseghi.  The members of the Audit Committee have substantial experience in assessing the performance of companies, gained as members of the Company’s Board of Directors and Audit Committee, as well as by serving in various capacities in other companies or governmental agencies.  As a result, they each have an understanding of financial statements. The Board believes that Behnam Movaseghi fulfills the role of the financial expert on this committee.

 

The Audit Committee regularly meets with our independent registered public accounting firm without the presence of management.

 

The Audit Committee operates under a charter approved by the Board of Directors.  The Audit Committee charter is available on our website. 

 

Compensation Committee

 

Our Compensation Committee annually establishes, subject to the approval of the Board of Directors and any applicable employment agreements, the compensation that will be paid to our executive officers during the coming year, as well as administers our stock-based benefit plans.  During the year ended December 31, 2022, the Compensation Committee consisted of Joshua Markowitz, committee chair, and Behnam Movaseghi.  Neither of these persons has been officers or employees of the Company at the time of his position on the committee, or, except as otherwise disclosed, had any relationship requiring disclosure herein.

 

The Compensation Committee operates under a charter approved by the Board of Directors.  The Compensation Committee charter is available on our website.

 

MEETINGS OF THE BOARD OF DIRECTORS AND COMMITTEES

 

During the year ended December 31, 2022 there were:

 

 

·

4 meetings of the Board of Directors

 

·

5 meetings of the Audit Committee

 

·

2 meetings of the Compensation Committee

 

 
23

Table of Contents

 

Section 16(a) Beneficial Ownership Reporting Compliance

 

Section 16(a) of the Exchange Act requires directors, executive officers and persons who beneficially own more than 10% of our common stock (collectively, “Reporting Persons”) to file initial reports of ownership and reports of changes in ownership of our common stock with the SEC.  Reporting Persons are required by SEC regulations to furnish us with copies of all Section 16(a) reports they file.  To our knowledge, based solely on our review of the copies of such reports received or written representations from certain Reporting Persons that no other reports were required, we believe that during the year ended December 31, 2022 all Reporting Persons timely complied with all applicable filing requirements.

 

Corporate Governance - Code of Ethics

 

We have adopted a Corporate Code of Business Ethics (the “Code”) that applies to all employees, including our principal executive officer, principal financial officer, and directors of the Company.  A copy of the Code can be found on our website, www.vasocorporation.com.  The Code is broad in scope and is intended to foster honest and ethical conduct, including accurate financial reporting, compliance with laws and the like. If any substantive amendments are made to the Code or if there is any grant of waiver, including any implicit waiver, from a provision of the Code to our Chief Executive Officer or Chief Financial Officer, we will disclose the nature of such amendment or waiver in a Current Report on Form 8-K.

 

Executive Officers of the Registrant

 

As of March 24, 2023 our executive officers are:

 

Name of Officer

 

Age

 

Position held with the Company

Jun Ma, PhD

 

59

 

President, Chief Executive Officer

Peter C. Castle

 

54

 

Chief Operating Officer

Jane Moen

 

43

 

President of Vasohealthcare

Michael J. Beecher

 

78

 

Co-Chief Financial Officer and Secretary

Jonathan P. Newton

 

62

 

Co-Chief Financial Officer and Treasurer

  

Peter Castle was a director from August 2010 to December 2019 and was appointed the Chief Operating Officer of the Company after the NetWolves acquisition in June 2015.  Prior to the acquisition, Mr. Castle was the President and Chief Executive Officer of NetWolves Network Services, LLC, where he has been employed since 1998.  At NetWolves, Mr. Castle also held the position of Chief Financial Officer from 2001 until October 2009, Vice President of Finance since January 2000, Controller from August 1998 until December 1999 and Treasurer and Secretary from August 1999.

 

Michael J. Beecher, CPA, was Chief Financial Officer of the Company from September 2011 and Co-Chief Financial Officer since December 10, 2019.  Prior to joining Vasomedical in 2011, Mr. Beecher was Chief Financial Officer of Direct Insite Corp., a publicly held company, from December 2003 to September 2011.  Prior to his position at Direct Insite, Mr. Beecher was Chief Financial Officer and Treasurer of FiberCore, Inc., a publicly held company in the fiber-optics industry.  From 1989 to 1995 he was Vice-President Administration and Finance at the University of Bridgeport.  Mr. Beecher began his career in public accounting with Haskins & Sells, an international public accounting firm.  He is a graduate of the University of Connecticut, a Certified Public Accountant and a member of the American Institute of Certified Public Accountants.

 

Jonathan P. Newton served as Chief Financial Officer of the Company from September 1, 2010 to September 8, 2011, Vice President of Finance and Treasurer until December 10, 2019, and is currently Co-Chief Financial Officer and Treasurer.  From June 2006 to August 2010, Mr. Newton was Director of Budgets and Financial Analysis for Curtiss-Wright Flow Control.   Prior to his position at Curtiss-Wright Flow Control, Mr. Newton was Vasomedical’s Director of Budgets and Analysis from August 2001 to June 2006.  Prior positions included Controller of North American Telecommunications Corp., Accounting Manager for Luitpold Pharmaceuticals, positions of increasing responsibility within the internal audit function of the Northrop Grumman Corporation and approximately three and one half years as an accountant for Deloitte Haskins & Sells, during which time Mr. Newton became a Certified Public Accountant.  Mr. Newton holds a B.S. in Accounting from SUNY at Albany, and a B.S. in Mechanical Engineering from Hofstra University.

 

 
24

Table of Contents

 

ITEM 11 - EXECUTIVE COMPENSATION

 

The following table sets forth the annual and long-term compensation of our Chief Executive Officer and each of our most highly compensated officers and employees who were serving as executive officers or employees at the end of the last completed fiscal year for services rendered for the years ended December 31, 2022 and 2021.

 

Summary Compensation Table

 

Name and Principal Position

 

Year

 

Salary ($)

 

 

Bonus ($)

 

 

Stock

Awards ($) (1)

 

Option

Awards ($)

 

Non-Equity

Incentive Plan

Compensation ($)

 

Nonqualified

Deferred

Compensation

Earnings ($)

 

All Other

Compensation ($) (2)

 

 

Total ($)

 

Jun Ma, PhD

 

2022

 

 

500,000

 

 

 

220,000

 

 

 

 

 

 

 

 

 

 

 

85,323

 

 

 

805,323

 

Chief Executive Officer

 

2021

 

 

500,000

 

 

 

100,000

 

 

 

 

 

 

 

 

 

 

 

87,041

 

 

 

687,041

 

Peter C. Castle

 

2022

 

 

350,000

 

 

 

20,000

 

 

 

 

 

 

 

 

 

 

 

13,368

 

 

 

383,368

 

Chief Operating Officer

 

2021

 

 

350,000

 

 

 

35,000

 

 

 

 

 

 

 

 

 

 

 

13,950

 

 

 

398,950

 

Jane Moen

 

2022

 

 

293,750

 

 

 

245,000

 

 

 

 

 

 

 

 

 

 

 

11,145

 

 

 

549,895

 

President of VasoHealthcare

 

2021

 

 

275,000

 

 

 

225,000

 

 

 

 

 

 

 

 

 

 

 

26,931

 

 

 

526,931

 

Michael J. Beecher

 

2022

 

 

102,000

 

 

 

20,000

 

 

 

 

 

 

 

 

 

 

 

3,362

 

 

 

125,362

 

Co-Chief Financial Officer and Secretary

 

2021

 

 

108,000

 

 

 

20,000

 

 

 

 

 

 

 

 

 

 

 

3,360

 

 

 

131,360

 

Jonathan P. Newton

 

2022

 

 

215,000

 

 

 

120,000

 

 

 

 

 

 

 

 

 

 

 

11,416

 

 

 

346,416

 

Co-Chief Financial Officer and Treasurer

 

2021

 

 

200,000

 

 

 

50,000

 

 

 

 

 

 

 

 

 

 

 

10,261

 

 

 

260,261

 

 

 __________________

(1)

Represents fair value on the date of grant. See Note B to the Consolidated Financial Statements included in our Form 10–K for the year ended December 31, 2022 for a discussion of the relevant assumptions used in calculating grant date fair value.

(2)

Represents tax gross-ups, lodging and vehicle allowances, Company-paid life insurance, and amounts matched in the Company’s 401(k) Plan.

 

Outstanding Equity Awards at Last Fiscal Year End

 

The following table provides information concerning outstanding options, unvested stock and equity incentive plan awards for our named executive officers at December 31, 2022:

 

 

 

Option Awards

 

Stock Awards

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Name

 

Number of

Securities

Underlying

Unexercised

Options -

Exercisable

 

Number of

Securities

Underlying

Unexercised

Options -

Unexercisable

 

Equity Incentive

Plan Awards:

Number of

Underlying

Unexercised Unearned

Options

 

Option

Exercise

Price

 

Option

Expiration

Date

 

Number of

Shares or

Units of

Stock That

Have Not

Vested

 

 

Market Value of Shares or Units

of Stock That

Have Not

Vested

 

 

Equity Incentive

Plan Awards:

Number of Unearned

Shares, Units

or Other Rights

That Have Not

Vested

 

 

Equity Incentive

Plan Awards:

Market or Payout

Value of Unearned

Shares, Units or

Other Rights That

Have Not Vested

 

Jun Ma, PhD

 

 

 

 

 

 

 

 

 

 

 

 

1,000,000

 

 

 

50,000

 

 

 

-

 

 

 

-

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Jane Moen

 

 

 

 

 

 

 

 

 

 

 

 

400,000

 

 

 

20,000

 

 

 

-

 

 

 

-

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Jonathan P. Newton

 

 

 

 

 

 

 

 

 

 

 

 

200,000

 

 

 

10,000

 

 

 

-

 

 

 

-

 

 

 
25

Table of Contents

 

The future vesting dates of the above stock awards are:

 

Name

 

Number of Shares or Units of Stock That Have Not Vested

 

 

Vesting Date

 

Jun Ma, PhD

 

 

1,000,000

 

 

6/1/2023

 

 

 

 

 

 

 

 

 

Jane Moen

 

 

200,000

 

 

4/1/2023

 

 

 

 

200,000

 

 

4/1/2024

 

 

 

 

 

 

 

 

 

Jonathan P. Newton

 

 

100,000

 

 

1/1/2023

 

 

 

 

100,000

 

 

1/1/2024

 

 

Employment Agreements

 

On May 10, 2019, the Company modified its Employment Agreement with its President and Chief Executive Officer, Dr. Jun Ma, to provide for a five-year term with extensions, unless earlier terminated by the Company, but in no event can it extend beyond May 31, 2026. The Employment Agreement provides for annual compensation of $500,000. Dr. Ma shall be eligible to receive a bonus for each fiscal year during the employment term. The amount and the occasion for payment of such bonus, if any, shall be at the discretion of the Board of Directors. Dr. Ma shall also be eligible for an award under any long-term incentive compensation plan and grants of options and awards of shares of the Company’s stock, as determined at the Board of Directors’ discretion. The Employment Agreement further provides for reimbursement of certain expenses, and certain severance benefits in the event of termination prior to the expiration date of the Employment Agreement.

 

On December 31, 2022, the Company executed an Employment Agreement with the President of its VasoHealthcare subsidiary, Ms. Jane Moen, to provide for a twenty-seven month initial term with extensions, unless earlier terminated by the Company, but in no event can it extend beyond December 31, 2026. The Employment Agreement provides for annual base compensation of $350,000. Ms. Moen shall be eligible to receive bonuses for each fiscal year during the employment term. The amount and the occasion for payment of such bonuses, if any, shall be based on employment status and achieving certain operating targets. Ms. Moen shall also be eligible for an award under any long-term incentive compensation plan and grants of options and awards of shares of the Company’s stock, as determined at the Board of Directors’ discretion. The Employment Agreement further provides for reimbursement of certain expenses, and certain severance benefits in the event of termination prior to the expiration date of the Employment Agreement.

 

401(k) Plan

 

                 The Company maintains a defined contribution plan to provide retirement benefits for its employees - the Vaso Corporation 401(k) Plan adopted in April 1997.  As allowed under Section 401(k) of the Internal Revenue Code, the plan provides tax-deferred salary deductions for eligible employees. Employees are eligible to participate in the next quarter enrollment period after employment under the Vaso Corporation Plan. Participants may make voluntary contributions to the plan up to 80% of their compensation under the Vaso Corporation Plan. In the years ended December 31, 2022 and 2021 the Company made discretionary contributions of approximately $112,000 and $129,000, respectively, to match a percentage of employee contributions.

 

 
26

Table of Contents

 

Director’s Compensation

 

                Each of the non-employee directors receives an annual fee of $30,000 as well as a fee of $2,500 for each Board of Directors and Committee meeting attended, except for the Chairman who receives a flat fee of $120,000 per annum.  Committee chairs receive an additional annual fee of $5,000.  Each director also received a fee of $20,000 plus an additional $20,000 per committee seat. 

 

 

 

Fees Earned or Paid in Cash

 

 

Stock Awards

 

 

Option Awards

 

 

Non-equity Incentive Plan Compensation

 

 

Nonqualified Deferred Compensation Earnings

 

 

All Other Compensation (1)

 

 

Total

 

Name

 

($)

 

 

($)

 

 

($)

 

 

($)

 

 

($)

 

 

($)

 

 

($)

 

David Lieberman

 

 

60,000

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

28,649

 

 

 

88,649

 

Joshua Markowitz

 

 

160,000

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

160,000

 

Behnam Movaseghi

 

 

117,500

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

117,500

 

Edgar Rios

 

 

97,500

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

97,500

 

 

(1)

Represents health benefit premiums.

 

Compensation Committee Interlocks and Insider Participation

 

During the year ended December 31, 2022, the Compensation Committee consisted of Joshua Markowitz, committee chair, and Behnam Movaseghi.  Neither of these persons were officers or employees of the Company during the time they held positions on the committee, or, except as otherwise disclosed, had any relationship requiring disclosure herein.

 

ITEM 12 - SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS

 

The following table sets forth the beneficial ownership of shares of our common stock as of March 24, 2023 of (i) each person known by us to beneficially own 5% or more of the shares of outstanding common stock, based solely on filings with the SEC, (ii) each of our executive officers and directors, and (iii) all of our executive officers and directors as a group. Except as otherwise indicated, all shares are beneficially owned, and investment and voting power is held by the persons named as owners.  To our knowledge, except under community property laws or as otherwise noted, the persons and entities named in the table have sole voting and sole investment power over their shares of our common stock. Unless otherwise indicated, each beneficial owner listed below maintains a mailing address of c/o Vaso Corporation, 137 Commercial Street, Plainview, New York 11803.

 

Name of Beneficial Owner

 

Common Stock Beneficially

Owned (1)

 

 

% of Common Stock (2)

 

Joshua Markowitz ** (3)

 

 

56,088,318

 

 

 

32.03%

Jun Ma, PhD **

 

 

10,298,146

 

 

 

5.88%

Peter Castle **

 

 

3,125,000

 

 

 

1.78%

Edgar Rios **

 

 

1,625,000

 

 

*

 

Jane Moen **

 

 

1,605,087

 

 

*

 

David Lieberman **

 

 

1,599,200

 

 

*

 

Jonathan Newton **

 

 

1,275,000

 

 

*

 

Michael J. Beecher **

 

 

1,240,400

 

 

*

 

Behnam Movaseghi **

 

 

1,189,404

 

 

*

 

 

 

 

 

 

 

 

 

 

** Directors and executive officers as a group (9 persons)

 

 

78,045,555

 

 

 

44.56%

 

 

 

* Less than 1% of the Company’s common stock

 

 

 

 

(1)

No officer or director owns more than one percent of the issued and outstanding common stock of the Company unless otherwise indicated.

 

(2)

Applicable percentages are based on 175,127,878 shares of common stock outstanding as of March 24, 2023, adjusted as required by rules promulgated by the SEC.

 

(3)

Joshua Markowitz is the record holder of 350,000 shares of our common stock. Additionally, 55,738,318 shares are held in trust funds of which Mr. Markowitz is the sole trustee.

 

 
27

Table of Contents

 

Equity Compensation Plan Information

 

                We maintain various stock plans under which stock options and stock grants are awarded at the discretion of our Board of Directors or its Compensation Committee.  The purchase price of the shares under the plans and the shares subject to each option granted is not less than the fair market value on the date of the grant.  The term of each option is generally five years and is determined at the time of the grant by our board of directors or the compensation committee.  The participants in these plans are officers, directors, employees, and consultants of the Company and its subsidiaries and affiliates.

 

 

Plan category

 

(a) Number of securities to be issued upon exercise of outstanding options, warrants and rights

 

 

(b) Weighted-average exercise price of outstanding options, warrants and rights

 

 

(c) Number of securities remaining available for future issuance under equity compensation plans (excluding securities reflected in column (a))

 

 

 

 

 

 

 

 

 

 

 

Equity Compensation

 

 

 

 

 

 

 

 

 

plans approved by

 

 

 

 

 

 

 

 

 

security holders

 

 

-

 

 

$0.00

 

 

 

-

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Equity Compensation

 

 

 

 

 

 

 

 

 

 

 

 

plans not approved

 

 

 

 

 

 

 

 

 

 

 

 

by security holders (1)

 

 

1,050,000

 

 

$0.00

 

 

 

9,955,580

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Total

 

 

1,050,000

 

 

 

 

 

 

 

9,955,580

 

 

 

(1)

Includes 50,000 shares of restricted common stock granted, but unissued, under the 2013 Plan, and 1,000,000 shares of restricted common stock granted, but unissued, under the 2016 Plan.  The exercise price for the stock grants is zero.  755,580 shares, 700,000 shares, and 8,500,000 shares remain available for future grants under the 2013 Plan, 2016 Plan, and 2019 Plan, respectively.

 

See Note P to the Consolidated Financial Statements for description of the material features of our current stock plans not approved by stockholders.

  

ITEM 13 - CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE

 

Director Independence

 

We have adopted the NASDAQ Stock Market’s standards for determining the independence of directors. Under these standards, an independent director means a person other than an executive officer or one of our employees or any other individual having a relationship which, in the opinion of the Board of Directors, would interfere with the exercise of independent judgment in carrying out the responsibilities of a director. In addition, the following persons shall not be considered independent:

 

 

·

a director who is, or at any time during the past three years was, employed by us;

 

·

a director who accepted or who has a family member who accepted any compensation from us in excess of $100,000 during any period of twelve consecutive months within the three years preceding the determination of independence, other than the following:

 

o

compensation for service on the Board of Directors or any committee thereof;

 

o

compensation paid to a family member who is one of our employees (other than an executive officer); or

 

o

under a tax-qualified retirement plan, or non-discretionary compensation;

 

 
28

Table of Contents

 

 

·

a director who is a family member of an individual who is, or at any time during the past three years was, employed by us as an executive officer;

 

·

a director who is, or has a family member who is, a partner in, or a controlling stockholder or an executive officer of, any organization to which we made, or from which we received, payments for property or services in the current or any of the past three fiscal years that exceed 5% of the recipient’s consolidated gross revenues for that year, or $200,000, whichever is more, other than the following:

 

o

payments arising solely from investments in our securities; or

 

o

payments under non-discretionary charitable contribution matching programs;

 

·

a director who is, or has a family member who is, employed as an executive officer of another entity where at any time during the past three years any of our executive officers served on the compensation committee of such other entity; or

 

·

a director who is, or has a family member who is, a current partner of our outside auditor, or was a partner or employee of our outside auditor who worked on our audit at any time during any of the past three years.

 

For purposes of the NASDAQ independence standards, the term “family member” means a person’s spouse, parents, children and siblings, whether by blood, marriage or adoption, or anyone residing in such person’s home.

 

The Board of Directors has assessed the independence of each non-employee director under the independence standards of the NASDAQ Stock Market set forth above, and has affirmatively determined that three of our non-employee directors (Mr. Rios, Mr. Markowitz and Mr. Movaseghi) are independent.

 

We expect each director to attend every meeting of the Board and the committees on which he serves as well as the annual meeting.  In the year ended December 31, 2022, all directors attended both the annual meeting and at least 75% of the meetings of the Board and the committees on which they served.

 

ITEM 14 - PRINCIPAL ACCOUNTING FEES AND SERVICES

 

                UHY LLP and MaloneBailey LLP, as our respective current and prior independent registered public accounting firm, performed the audits of our consolidated financial statements for the years ended December 31, 2022 and 2021, respectively.  The following table sets forth all fees for such periods:

 

 

 

2022

 

 

2021

 

Audit fees

 

$235,000

 

 

$228,000

 

Tax fees

 

 

-

 

 

 

-

 

All other fees

 

 

-

 

 

 

-

 

 

 

 

 

 

 

 

 

 

Total

 

$235,000

 

 

$228,000

 

 

                The Audit Committee has adopted a policy that requires advance approval of all audit, audit-related, tax services, and other services performed by the Company’s independent auditor.  Accordingly, the Audit Committee must approve the permitted service before the independent auditor is engaged to perform it.  In accordance with such policies, the Audit Committee approved 100% of the services relative to the above fees.

 

 
29

Table of Contents

 

PART IV

 

ITEM 15 – EXHIBITS AND FINANCIAL STATEMENT SCHEDULES

 

Financial Statements and Financial Statement Schedules

  

 

(1)

See Index to Consolidated Financial Statements on page F-1 at beginning of attached financial statements.

 

(a)

Exhibits

 

 

 

 

 

 

(3)(i)

(a)

Restated Certificate of Incorporation (2)

 

 

(b)

Certificate of Designations of Preferences and Rights of Series E Convertible Preferred Stock (3)

 

 

(c)

Certificate of Amendment to Certificate of Incorporation (11)

 

(3)(ii)

 

By-Laws (1)

 

(4)

(a)

Specimen Certificate for Common Stock (1)

 

 

(b)

Specimen Certificate for Series E Convertible Preferred Stock (5)

 

 

(c)

Secured Subordinated Note, dated as of May 29, 2015, between Vasomedical, Inc. and MedTechnology Investments LLC (9)

 

(10)

(a)

Form of Stock Purchase Agreement (3)

 

 

(b)

Redacted Sales Representative Agreement between GE Healthcare Division of General Electric Company and Vaso Diagnostics, Inc. d/b/a VasoHealthcare, a subsidiary of Vasomedical, Inc. dated as of May 19, 2010 (4).

 

 

(c)

2010 Stock Plan (5).

 

 

(d)

Employment Agreement entered into as of March 21, 2011 between Vasomedical, Inc. and Jun Ma, as amended. (8)

 

 

(e)

Stock Purchase Agreement dated as of August 19, 2011 among Vasomedical, Inc., Fast Growth Enterprises Limited (FGE) and the FGE Shareholders (6)

 

 

(f)

Amendment to Sales Representative Agreement between GE Healthcare Division of General Electric Company and Vaso Diagnostics, Inc. d/b/a VasoHealthcare, a subsidiary of Vasomedical, Inc. dated as of June 20, 2012 (7)

 

 

(g)

2013 Stock Plan (12)

 

 

(h)

Asset Purchase and Sale Agreement, dated as of May 29, 2015, by and among Vasomedical, Inc., VasoTechnology, Inc., NetWolves, LLC and NetWolves Corporation (9)

 

 

(i)

Subordinated Security Agreement dated as of May 29, 2015 by and between Vasomedical, Inc. and MedTechnology Investments LLC (9)

 

 

(j)

Employment Agreement dated as of June 1, 2015 between Vasomedical, Inc. and Peter C. Castle (10)

 

 

(k)

2016 Stock Plan (13)

 

 

(l)

2019 Stock Plan (14)

  

 
30

Table of Contents

 

 

(21)

 

Subsidiaries of the Registrant

 

Name

 

State of Incorporation

 

Percentage Owned by Company

 

 

 

 

 

Vaso Diagnostics, Inc.

 

 New York

 

100%

VasoMedical, Inc.

 

 Delaware

 

100%

Vasomedical Global Corp.

 

 New York

 

100%

Vasomedical Solutions, Inc.

 

 New York

 

100%

VasoHealthcare IT Corp.

 

 Delaware

 

100%

VasoTechnology, Inc.

 

 Delaware

 

100%

NetWolves Network Services LLC

 

 Florida

 

100% 

EECP Global Corporation

 

 New York

 

49%

Fast Growth Enterprises Limited

 

 British Virgin Islands

 

100%

 

 

(31)

 

Certification Reports pursuant to Securities Exchange Act Rule 13a - 14

 

(32)

 

Certification Reports pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

 __________________________

 

(1)

Incorporated by reference to Registration Statement on Form S-18, No. 33-24095.

 

(2)

Incorporated by reference to Registration Statement on Form S-1, No. 33-46377 (effective 7/12/94).

 

(3)

Incorporated by reference to Report on Form 8-K dated June 21, 2010.

 

(4)

Incorporated by reference to Report on Form 8-K/A dated May 19, 2010 and filed November 9, 2010.

 

(5)

Incorporated by reference to Report on Form 10-K for the fiscal year ended May 31, 2010.

 

(6)

Incorporated by reference to Report on Form 10-K for the fiscal year ended May 31, 2011.

 

(7)

Incorporated by reference to Report on Form 8-K dated June 20, 2012.

 

(8)

Incorporated by reference to Report on Form 8-K dated March 21, 2011.

 

(9)

Incorporated by reference to Report on Form 8-K dated May 29, 2015.

 

(10)

Incorporated by reference to Report on Form 8-K dated October 8, 2015.

 

(11)

Incorporated by reference to Report on Form 10-Q for the quarter ended September 30, 2016.

 

(12)

Incorporated by reference to Report on Form 10-Q for the quarter ended September 30, 2013.

 

(13)

Incorporated by reference to Report on Form 10-Q for the quarter ended June 30, 2016.

 

(14)

Incorporated by reference to Report on Form 10-K for the year ended December 31, 2019.

 

 
31

Table of Contents

 

SIGNATURES

 

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, we have duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized on the 31st day of March 2023.

 

 

VASO CORPORATION

    
By:/s/ Jun Ma

 

 

Jun Ma

 
  

President, Chief Executive Officer,

 
  and Director (Principal Executive Officer) 

 

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below on March 31, 2023, by the following persons in the capacities indicated:

 

/s/ Jun Ma

 

President, Chief Executive Officer

 

Jun Ma

 

and Director (Principal Executive Officer)

 

 

 

 

 

/s/ Michael Beecher

 

Chief Financial Officer (Principal Financial Officer)

 

Michael Beecher

 

 

 

 

 

 

 

/s/ Joshua Markowitz

 

Chairman of the Board

 

Joshua Markowitz

 

 

 

 

 

 

 

/s/ David Lieberman

 

Vice Chairman of the Board

 

David Lieberman

 

 

 

 

 

 

 

/s/ Jane Moen

 

Director

 

Jane Moen

 

 

 

 

 

 

 

/s/ Edgar Rios

 

Director

 

Edgar Rios

 

 

 

 

 

 

 

/s/ Behnam Movaseghi

 

Director

 

Behnam Movaseghi

 

 

 

 

 
32

Table of Contents

 

Vaso Corporation and Subsidiaries

 

INDEX TO CONSOLIDATED FINANCIAL STATEMENTS

 

For the years ended December 31, 2022 and 2021

 

 

Page

 

 

 

 

 

Report of Independent Registered Public Accounting Firm

 

F-2

 

 

 

 

 

Financial Statements

 

 

 

Consolidated Balance Sheets as of December 31, 2022 and 2021

 

F-6

 

Consolidated Statements of Operations and Comprehensive Income for the years ended December 31, 2022 and 2021

 

F-7

 

Consolidated Statements of Changes in Stockholders’ Equity for the years ended December 31, 2022 and 2021

 

F-8

 

Consolidated Statements of Cash Flows for the years ended December 31, 2022 and 2021

 

F-9

 

Notes to Consolidated Financial Statements

 

F-10 – F-34

 

 

 
F-1

Table of Contents

 

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

 

To the Stockholders and Board of Directors of

Vaso Corporation and Subsidiaries

 

Opinion on the Financial Statements

 

We have audited the accompanying consolidated balance sheet of Vaso Corporation and Subsidiaries (the “Company”) as of December 31, 2022, and the related consolidated statements of operations and comprehensive income, stockholders’ equity and cash flows for the year then ended, and the related notes (collectively referred to as the financial statements).  In our opinion, the financial statements referred to above present fairly, in all material respect, the financial position of the Company as of December 31, 2022, and the results of its operations and its cash flows for the year then ended, in conformity with accounting principles generally accepted in the United States of America. 

 

Basis for Opinion

 

These financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s financial statements based on our audit. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (“PCAOB”) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

 

We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audit, we are required to obtain an understanding of internal control over financial reporting, but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion.

 

Our audit included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audit also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audit provides a reasonable basis for our opinion.

 

Critical Audit Matters

 

The critical audit matters communicated below are matters arising from the current-period audit of the financial statements that were communicated or required to be communicated to the audit committee and that (1) relates to an account or disclosure that is material to the financial statements and (2) involved especially challenging, subjective, or complex judgments. The communication of the critical audit matters does not alter in any way our opinion on the financial statements, taken as a whole, and we are not, by communicating the critical audit matters below, providing a separate opinion on the critical audit matters or on the accounts or disclosures to which they relate.

 

 
F-2

 

 

To the Stockholders and Board of Directors of

Vaso Corporation and Subsidiaries

Page Two

 

Critical Audit Matter - Revenue recognized from sales commission with General Electric Healthcare (GEHC)

 

As discussed in Notes A and B to the financial statements, the Company, through its wholly owned subsidiary VasoHealthcare (VHC), was appointed the exclusive representative for the sale of GEHC’s diagnostics imaging equipment to specific market segments and recognized sales commission revenue when the underlying equipment and services have been delivered or completed by GEHC. VHC has total sales commission revenue of approximately $37.3 million for the year ended December 31, 2022, which is concentrated solely with GEHC.

 

We identified the testing of sales commission revenue generated from GEHC as a critical audit matter. Specifically, the sales commission revenue is calculated through complicated formulas including order data from various files obtained from GEHC monthly and is stored in a spreadsheet file based on the master agreement and various subsequent amendments between GEHC and the Company. The audit of the spreadsheet file requires significant efforts from auditors due to the volume of data, size of the file, and complexity of formulas within the spreadsheet file.

 

How the Critical Audit Matter Was Addressed in the Audit

During the audit, we obtained an understanding of the design and implementation of the internal control over the revenue recognition process. For selected orders based on our judgment, we tested the Company’s master file for completeness, traced the data source to the various files that are further directly confirmed with GEHC on sales order and delivery, tested the formulas for its accuracy and reasonableness and agreed the commission rates to the agreements between GEHC and further confirmed with GEHC as to which sales region achieved the target order volume.

 

Critical Audit Matter – Valuation of Deferred Tax Assets

 

As discussed in Note B to the financial statements, the Company records a valuation allowance to reduce total net deferred tax assets when a judgment is made that is considered more likely than not that a tax benefit will not be realized. At December 31, 2022, the Company recognized net deferred tax assets of approximately $5 million and an income tax benefit of approximately $4.7 million for the year ended December 31, 2022 based on a determination that the realization of these deferred tax assets are probable. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences will become deductible.

 

We identified the realizability of deferred tax assets as a critical audit matter. The principal considerations for our determination that the realizability of deferred tax assets is a critical audit matter are that the forecast of future taxable income is subject to a high level of estimation and the determination of any limitations on the utilization of net operating loss carryforwards involve complex calculations and judgment. There is inherent uncertainty and subjectivity related to management’s judgments and assumptions regarding the Company’s future taxable income, which are complex in nature and require significant auditor judgment.

 

How the Critical Audit Matter Was Addressed in the Audit

 

During the audit, we obtained an understanding of the controls relating to the assessment on recoverability of the deferred tax assets and tested the reasonableness of management’s corporate model used to estimate future taxable income by comparing the estimates to historical taxable income, evidence obtained in other areas of the audit and management’s history and ability to carry out its plans and involved income tax professionals with specialized skills and knowledge, who assisted in assessing the Company’s application of tax laws and evaluating the realizability of deferred tax assets.

 

/s/ UHY LLP

 

We have served as the Company’s auditor since 2022.

 

Sterling Heights, Michigan

March 31, 2023

 

 
F-3

 

 

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

 

To the Stockholders and Board of Directors of

Vaso Corporation

 

Opinion on the Financial Statements

 

We have audited the accompanying consolidated balance sheets of Vaso Corporation and its subsidiaries (collectively, the “Company”) as of December 31, 2021, and the related consolidated statements of operations and comprehensive income, stockholders’ equity, and cash flows for the year then ended, and the related notes (collectively referred to as the “financial statements”). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2021, and the results of their operations and their cash flows for the year then ended, in conformity with accounting principles generally accepted in the United States of America.

 

Basis for Opinion

 

These financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (“PCAOB”) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

 

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion.

 

Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.

 

Critical Audit Matters

 

The critical audit matters communicated below are matters arising from the current period audit of the financial statements that were communicated or required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the financial statements, taken as a whole, and we are not, by communicating the critical audit matters below, providing separate opinions on the critical audit matters or on the accounts or disclosures to which they relate.

 

Revenue recognized from commission sales with General Electric Healthcare (GEHC)

 

Description of the Matter

 

As discussed in Notes A and B to the consolidated financial statements, the Company, through its wholly-owned subsidiary VasoHealthcare (VHC), was appointed the exclusive representative for the sale of GEHC diagnostics imaging equipment to specific market segments and recognized commission revenue when the underlying equipment/services have been delivered/completed by GEHC. VHC has a total commission revenue of $29,441 (in thousands) for the year ended December 31, 2022, and 100% of it is with GEHC.

 

 
F-4

Table of Contents

 

We identified the testing of commission revenue generated from GEHC as a critical audit matter. Specifically, the commission revenue is calculated through complicated formula including order data from various files obtained from GEHC monthly and is stored in a excel file and based on the one master agreement and various subsequent amendments between GEHC and the Company. The audit of the excel file requires significant efforts from auditors due to the volume of data, the size of the file, and the complexity of the formulas inside of the file.

 

How We Addressed the Matter in Our Audit

 

During the audit, we obtained an understanding of the design and implementation of the internal control over the revenue recognition process including certain general computer controls, applications controls and monitor controls and tested access control of the master excel worksheet.  For selected orders based on our judgment, we inspected the Company’s master file, traced the data source to the various files that are further directly confirmed with GEHC, tested the formula for its accuracy and reasonableness and agreed the commission rates and incentives to the agreements between GEHC and further confirmed with GEHC on the incentives as to which sales region achieved the incentive target.

 

/s/ Malone Bailey LLP

 

www.malonebailey.com

 

We have served as the Company’s auditor from 2019 to 2022.

 

Houston, Texas

March 31, 2022

 

 
F-5

Table of Contents

 

Vaso Corporation and Subsidiaries

 

CONSOLIDATED BALANCE SHEETS

(in thousands, except share and per share data)

 

 

 

December 31, 2022

 

 

December 31, 2021

 

 

 

 

 

 

 

 

ASSETS

 

 

 

 

 

 

CURRENT ASSETS

 

 

 

 

 

 

Cash and cash equivalents

 

$11,821

 

 

$6,025

 

Short-term investments

 

 

8,504

 

 

 

629

 

Accounts and other receivables, net of an allowance for doubtful accounts and commission adjustments of $6,947 at December 31, 2022 and $5,804 at December 31, 2021

 

 

15,524

 

 

 

15,393

 

Receivables due from related parties

 

 

421

 

 

 

66

 

Inventories, net

 

 

1,473

 

 

 

1,147

 

Deferred commission expense

 

 

3,249

 

 

 

3,549

 

Prepaid expenses and other current assets

 

 

1,008

 

 

 

994

 

Total current assets

 

 

42,000

 

 

 

27,803

 

 

 

 

 

 

 

 

 

Property and equipment, net of accumulated depreciation of $9,787 at December 31, 2022 and $10,512 at December 31, 2021

 

 

1,340

 

 

 

2,172

 

Operating lease right of use assets

 

 

1,568

 

 

 

915

 

Goodwill

 

 

15,614

 

 

 

15,722

 

Intangibles, net

 

 

1,511

 

 

 

2,041

 

Other assets, net

 

 

4,726

 

 

 

2,446

 

Investment in EECP Global

 

 

889

 

 

 

1,043

 

Deferred tax assets, net

 

 

5,007

 

 

 

219

 

Total assets

 

$72,655

 

 

$52,361

 

 

 

 

 

 

 

 

 

 

LIABILITIES AND STOCKHOLDERS' EQUITY

 

 

 

 

 

 

 

 

CURRENT LIABILITIES

 

 

 

 

 

 

 

 

Accounts payable

 

$2,270

 

 

$2,797

 

Accrued commissions

 

 

3,720

 

 

 

2,705

 

Accrued expenses and other liabilities

 

 

8,891

 

 

 

7,489

 

Finance lease liabilities - current

 

 

122

 

 

 

222

 

Operating lease liabilities - current

 

 

745

 

 

 

562

 

Sales tax payable

 

 

809

 

 

 

719

 

Deferred revenue - current portion

 

 

15,139

 

 

 

16,495

 

Notes payable - current portion

 

 

9

 

 

 

8

 

Due to related party

 

 

3

 

 

 

3

 

Total current liabilities

 

 

31,708

 

 

 

31,000

 

 

 

 

 

 

 

 

 

 

LONG-TERM LIABILITIES

 

 

 

 

 

 

 

 

Notes payable, net of current portion

 

 

15

 

 

 

23

 

Finance lease liabilities, net of current portion

 

 

96

 

 

 

218

 

Operating lease liabilities, net of current portion

 

 

823

 

 

 

352

 

Deferred revenue, net of current portion

 

 

15,664

 

 

 

8,470

 

Other long-term liabilities

 

 

1,474

 

 

 

988

 

Total long-term liabilities

 

 

18,072

 

 

 

10,051

 

 

 

 

 

 

 

 

 

 

COMMITMENTS AND CONTINGENCIES (NOTE R)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

STOCKHOLDERS' EQUITY

 

 

 

 

 

 

 

 

Preferred stock, $0.01 par value; 1,000,000 shares authorized; nil shares issued and outstanding at December 31, 2022 and 2021

 

 

-

 

 

 

-

 

Common stock, $0.001 par value; 250,000,000 shares authorized; 185,435,965 shares issued at December 31, 2022 and 2021; 175,127,878 shares outstanding at December 31, 2022 and 2021

 

 

185

 

 

 

185

 

Additional paid-in capital

 

 

63,952

 

 

 

63,917

 

Accumulated deficit

 

 

(39,029)

 

 

(50,902)

Accumulated other comprehensive income (loss)

 

 

(233)

 

 

110

 

Treasury stock, at cost, 10,308,087 shares at December 31, 2022 and 2021

 

 

(2,000)

 

 

(2,000)

Total stockholders' equity

 

 

22,875

 

 

 

11,310

 

 Total liabilities and stockholders' equity

 

$72,655

 

 

$52,361

 

 

The accompanying notes are an integral part of these consolidated financial statements.

 

 
F-6

Table of Contents

 

Vaso Corporation and Subsidiaries

 

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME

 

(in thousands, except per share data)

 

 

 

Year ended December 31,

 

 

 

2022

 

 

2021

 

Revenues

 

 

 

 

 

 

Managed IT systems and services

 

$40,100

 

 

$42,916

 

Professional sales services

 

 

37,344

 

 

 

29,441

 

Equipment sales and services

 

 

2,573

 

 

 

3,222

 

Total revenues

 

 

80,017

 

 

 

75,579

 

 

 

 

 

 

 

 

 

 

Cost of revenues

 

 

 

 

 

 

 

 

Cost of managed IT systems and services

 

 

23,871

 

 

 

26,242

 

Cost of professional sales services

 

 

7,056

 

 

 

5,535

 

Cost of equipment sales and services

 

 

609

 

 

 

669

 

Total cost of revenues

 

 

31,536

 

 

 

32,446

 

Gross profit

 

 

48,481

 

 

 

43,133

 

 

 

 

 

 

 

 

 

 

Operating expenses

 

 

 

 

 

 

 

 

Selling, general and administrative

 

 

40,843

 

 

 

38,593

 

Research and development

 

 

605

 

 

 

1,721

 

Total operating expenses

 

 

41,448

 

 

 

40,314

 

Operating income

 

 

7,033

 

 

 

2,819

 

 

 

 

 

 

 

 

 

 

Other (expense) income

 

 

 

 

 

 

 

 

Interest and financing costs

 

 

(44)

 

 

(312)

Interest and other income, net

 

 

143

 

 

 

98

 

Gain on forgiveness of PPP loan

 

 

-

 

 

 

3,646

 

Loss on disposal of fixed assets

 

 

(2)

 

 

-

 

Total other income, net

 

 

97

 

 

 

3,432

 

 

 

 

 

 

 

 

 

 

Income before income taxes

 

 

7,130

 

 

 

6,251

 

Income tax benefit (expense)

 

 

4,743

 

 

 

(151)

Net income

 

 

11,873

 

 

 

6,100

 

 

 

 

 

 

 

 

 

 

Other comprehensive income

 

 

 

 

 

 

 

 

Foreign currency translation (loss) gain

 

 

(343)

 

 

94

 

Comprehensive income

 

$11,530

 

 

$6,194

 

 

 

 

 

 

 

 

 

 

Income per common share

 

 

 

 

 

 

 

 

- basic and diluted

 

$0.07

 

 

$0.04

 

 

 

 

 

 

 

 

 

 

Weighted average common shares outstanding

 

 

 

 

 

 

 

 

- basic

 

 

173,065

 

 

 

171,688

 

- diluted

 

 

174,656

 

 

 

173,771

 

 

 The accompanying notes are an integral part of these consolidated financial statements.

 

 
F-7

Table of Contents

 

Vaso Corporation and Subsidiaries

 

CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY

 

(in thousands)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Accumulated

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Additional

 

 

 

 

 

Other

 

 

Total

 

 

 

Common Stock

 

 

Treasury Stock

 

 

Paid-in-

 

 

Accumulated

 

 

Comprehensive

 

 

Stockholders

 

 

 

Shares

 

 

Amount

 

 

Shares

 

 

Amount

 

 

Capital

 

 

Deficit

 

 

Income (Loss)

 

 

Equity

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Balance at January 1, 2021

 

 

185,244

 

 

$185

 

 

 

(10,308)

 

 

(2,000)

 

$63,886

 

 

$(57,002)

 

$16

 

 

$5,085

 

Share-based compensation

 

 

192

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

31

 

 

 

-

 

 

 

-

 

 

 

31

 

Foreign currency translation gain

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

94

 

 

 

94

 

Net income

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

6,100

 

 

 

-

 

 

 

6,100

 

Balance at December 31, 2021

 

 

185,436

 

 

$185

 

 

 

(10,308)

 

$(2,000)

 

$63,917

 

 

$(50,902)

 

$110

 

 

$11,310

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Balance at January 1, 2022

 

 

185,436

 

 

$185

 

 

 

(10,308)

 

 

(2,000)

 

$63,917

 

 

$(50,902)

 

$110

 

 

$11,310

 

Share-based compensation

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

35

 

 

 

-

 

 

 

-

 

 

 

35

 

Foreign currency translation loss

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

(343)

 

 

(343)

Net income

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

11,873

 

 

 

-

 

 

 

11,873

 

Balance at December 31, 2022

 

 

185,436

 

 

$185

 

 

 

(10,308)

 

$(2,000)

 

$63,952

 

 

$(39,029)

 

$(233)

 

$22,875

 

 

The accompanying notes are an integral part of these consolidated financial statements.

 

 
F-8

Table of Contents

 

Vaso Corporation and Subsidiaries

 

CONSOLIDATED STATEMENTS OF CASH FLOWS

 

(in thousands)

 

 

 

Year ended

 

 

 

December 31,

 

 

 

2022

 

 

2021

 

Cash flows from operating activities

 

 

 

 

 

 

Net income

 

$11,873

 

 

$6,100

 

Adjustments to reconcile net income to net cash provided by operating activities

 

 

 

 

 

 

 

 

Depreciation and amortization

 

 

1,923

 

 

 

3,840

 

Deferred income taxes

 

 

(4,788)

 

 

52

 

Loss from investment in EECP Global

 

 

154

 

 

 

73

 

Gain on forgiveness of PPP loan

 

 

-

 

 

 

(3,646)

Provision for doubtful accounts and commission adjustments

 

 

63

 

 

 

448

 

Write-down of inventory

 

 

-

 

 

 

385

 

Share-based compensation

 

 

35

 

 

 

31

 

Changes in operating assets and liabilities:

 

 

 

 

 

 

 

 

Accounts and other receivables

 

 

(243)

 

 

(6,052)

Due from related parties

 

 

(343)

 

 

(46)

Inventories

 

 

(416)

 

 

299

 

Deferred commission expense

 

 

300

 

 

 

(1,195)

Prepaid expenses and other current assets

 

 

(103)

 

 

162

 

Other assets, net

 

 

(2,422)

 

 

(212)

Accounts payable

 

 

(521)

 

 

(3,492)

Accrued commissions

 

 

1,094

 

 

 

1,497

 

Accrued expenses and other liabilities

 

 

1,392

 

 

 

2,372

 

Sales tax payable

 

 

108

 

 

 

94

 

Deferred revenue

 

 

5,838

 

 

 

7,260

 

Due to related party

 

 

(14)

 

 

(233)

Other long-term liabilities

 

 

486

 

 

 

78

 

Net cash provided by operating activities

 

 

14,416

 

 

 

7,815

 

 

 

 

 

 

 

 

 

 

Cash flows from investing activities

 

 

 

 

 

 

 

 

Purchases of equipment and software

 

 

(566)

 

 

(415)

Purchases of short-term investments

 

 

(8,000)

 

 

-

 

Redemption of short-term investments

 

 

149

 

 

 

155

 

Net cash used in investing activities

 

 

(8,417)

 

 

(260)

 

 

 

 

 

 

 

 

 

Cash flows from financing activities

 

 

 

 

 

 

 

 

Repayment on revolving lines of credit

 

 

-

 

 

 

(5,448)

Repayment of notes payable and finance lease obligations

 

 

(230)

 

 

(2,881)

Net cash used in financing activities

 

 

(230)

 

 

(8,329)

Effect of exchange rate differences on cash and cash equivalents

 

 

27

 

 

 

(20)

 

 

 

 

 

 

 

 

 

NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS

 

 

5,796

 

 

 

(794)

Cash and cash equivalents - beginning of period

 

 

6,025

 

 

 

6,819

 

Cash and cash equivalents - end of period

 

$11,821

 

 

$6,025

 

 

 

 

 

 

 

 

 

 

SUPPLEMENTAL DISCLOSURE OF CASH INFORMATION

 

 

 

 

 

 

 

 

Interest paid

 

$44

 

 

$347

 

Income taxes paid

 

$48

 

 

$113

 

 

 

 

 

 

 

 

 

 

SUPPLEMENTAL SCHEDULE OF NON-CASH INVESTING AND FINANCING ACTIVITIES

 

 

 

 

 

 

 

 

Initial recognition of operating lease right of use asset and liability

 

$1,396

 

 

$783

 

 

The accompanying notes are an integral part of these consolidated financial statements.

 

 
F-9

Table of Contents

  

Vaso Corporation and Subsidiaries

 

 NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

 

For the Years Ended December 31, 2022 and 2021

 

NOTE A – DESCRIPTION OF BUSINESS

 

Vaso Corporation was incorporated in Delaware in July 1987.  For most of its history, the Company was a single-product company designing, manufacturing, marketing and servicing its proprietary Enhanced External Counterpulsation, or EECP®, therapy systems, mainly for the treatment of angina. In 2010 it began to diversify its business operations. The Company changed its name to Vaso Corporation in 2016 to more accurately reflect the diversified nature of its business mixture, and continues to use the original name VasoMedical for its proprietary medical device subsidiary. Unless the context requires otherwise, all references to “we”, “our”, “us”, “Company”, “registrant”, “Vaso” or “management” refer to Vaso Corporation and its subsidiaries.     

 

Overview

 

Vaso Corporation principally operates in three distinct business segments in the healthcare equipment and information technology industries.  We manage and evaluate our operations, and report our financial results, through these three business segments.

 

 

·

IT segment, operating through a wholly-owned subsidiary VasoTechnology, Inc., primarily focuses on healthcare IT and managed network technology services;

 

 

 

 

·

Professional sales service segment, operating through a wholly-owned subsidiary Vaso Diagnostics, Inc. d/b/a VasoHealthcare, primarily focuses on the sale of healthcare capital equipment for GE HealthCare (“GEHC”) into the health provider middle market; and

 

 

 

 

·

Equipment segment, primarily focuses on the design, manufacture, sale and service of proprietary medical devices and software, operating through a wholly-owned subsidiary VasoMedical, Inc., which in turn operates through Vasomedical Solutions, Inc. for domestic business and Vasomedical Global Corp. for international business, respectively.

 

VasoTechnology

 

VasoTechnology, Inc. was formed in May 2015, at the time the Company acquired all of the assets of NetWolves, LLC and its affiliates, including the membership interests in NetWolves Network Services, LLC (collectively, “NetWolves”).  It currently consists of a managed network and security service division, NetWolves, and a healthcare IT application VAR (value added reseller) division, VasoHealthcare IT.

 

In June 2014, the Company began its IT segment business by executing the Value Added Reseller Agreement (“VAR Agreement”) with GEHC to become a national value added reseller of GEHC Digital’s software solutions such as Picture Archiving and Communication System (“PACS”), Radiology Information System (“RIS”), and related services, including implementation, training, management and support.  This business focuses primarily on customer segments currently served by VasoHealthcare on behalf of GEHC.  A new wholly owned subsidiary, VasoHealthcare IT Corp. (“VHC IT”), was formed to conduct the healthcare IT business.  The VAR Agreement with GEHC was terminated in 2021.

 

In May 2015, the Company further expanded its IT segment business by acquiring NetWolves.  NetWolves designs and delivers multi-network and multi-technology solutions as a managed network provider, and provides a complete single-source solution that includes design, network redundancy, application device management, real-time network monitoring, reporting and support systems as a comprehensive solution. 

 

 
F-10

Table of Contents

 

Vaso Corporation and Subsidiaries

 

 NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

 

For the Years Ended December 31, 2022 and 2021

 

 

VasoHealthcare

 

In May 2010, the Company launched its Professional Sales Service business through a wholly-owned subsidiary Vaso Diagnostics, Inc. d/b/a VasoHealthcare, which was appointed by GEHC as its exclusive representative for the sale of select GEHC diagnostic imaging equipment to specific market segments in the 48 contiguous states of the United States and the District of Columbia.  The original agreement (“GEHC Agreement”) has been extended several times and currently expires December 31, 2026, subject to earlier termination under certain conditions.

 

VasoMedical

 

The proprietary medical equipment business under VasoMedical traces back to 1995 when the Company began the proprietary Enhanced External Counterpulsation (EECP®) technology in the United States and has since diversified to include other medical hardware and software.  Vasomedical Global was formed in 2011 to combine and coordinate the various international operations including design, development, manufacturing, and sales of medical devices and software, while domestic activities are conducted under Vasomedical Solutions. 

 

Over the last decade the Company’s Equipment business has been significantly expanded from the original EECP®-only operations.  In September 2011, the Company acquired Fast Growth Enterprises Limited (“FGE”), a British Virgin Islands company, which owned or controlled two Chinese operating companies - Life Enhancement Technology Ltd. (“LET”) and Biox Instruments Co. Ltd. (“Biox”) - to expand its technical and manufacturing capabilities and to enhance its distribution network, technology, and product portfolio.  Biox was a variable interest entity (“VIE”) controlled by FGE through certain contracts and an option to acquire all the shares of Biox by FGE’s wholly owned subsidiary Gentone, and in March 2019 Gentone exercised its option to acquire all of the shares of Biox.  In August 2014, the Company, through Gentone, acquired all of the outstanding shares of Genwell Instruments Co. Ltd. (“Genwell”), which was formed in China in 2010 to develop the MobiCare® wireless multi-parameter patient monitoring system and holds intellectual property rights for this system. As a result, the Company has expanded its equipment products portfolio to include Biox™ series ambulatory patient monitoring systems, ARCS® series software for ECG and blood pressure analysis, and the MobiCare® patient monitoring device. 

 

In April 2014, the Company entered into a cooperation agreement with Chongqing PSK-Health Sci-Tech Development Co., Ltd. (“PSK”) of Chongqing, China, the leading manufacturer of external counter pulsation, or ECP, therapy systems in China, to form a joint venture company, VSK Medical Limited (“VSK”), a Cayman Islands company, for the global marketing, sale and advancement of ECP therapy technology.  The Company owned 49.9% of VSK, which commenced operations in January 2015. In March 2018, the Company terminated the cooperation agreement with PSK and sold its shares in VSK to PSK.  On May 20, 2020, the Company closed on the sale of 51% of the capital stock of its wholly-owned subsidiary EECP Global Corporation (“EECP Global”) to PSK. EECP Global was formed in September 2019 to hold all the assets and liabilities of its EECP business. Concurrently with the closing of the transaction, the Company signed a Management Service Agreement with EECP Global to provide management service for the business and operation of EECP Global in the United States. The agreement provides an initial term of three years starting April 1, 2020, the effective date of the sale, which is automatically renewable for additional one-year terms.  Pursuant to the agreement, EECP Global reimburses the Company all direct expenses and pays a monthly management fee during the term of the agreement.

 

NOTE B - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 

A summary of the significant accounting policies consistently applied in the preparation of the consolidated financial statements are as follows:

 

Principles of Consolidation

 

The consolidated financial statements include the accounts of Vaso Corporation, its wholly-owned subsidiaries, and the accounts of the companies over which we exercise control. Significant intercompany balances and transactions have been eliminated. 

 

 
F-11

Table of Contents

 

Vaso Corporation and Subsidiaries

 

 NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

 

For the Years Ended December 31, 2022 and 2021

 

 

Use of Estimates

 

The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”) requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Significant estimates and assumptions relate to estimates of commission adjustments due to order cancellations, collectability of accounts receivable, the realizability of deferred tax assets, stock-based compensation, values and lives assigned to acquired intangible assets, fair value of reporting units in connection with goodwill impairment test, the adequacy of inventory reserves, variable consideration, and allocation of contract transaction price to performance obligations.  Actual results could differ from those estimates.

 

Revenue Recognition

 

In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers (Topic 606).  Under the standard, revenue is recognized when a customer obtains control of promised goods or services in an amount that reflects the consideration the entity expects to receive in exchange for those goods or services. ASU 2014-09 replaced most existing revenue recognition guidance in U.S. GAAP. The new standard introduces a five-step process to be followed in determining the amount and timing of revenue recognition. It also provides guidance on accounting for costs incurred to obtain or fulfill contracts with customers, and establishes disclosure requirements which are more extensive than those required under prior U.S. GAAP.  Generally, we recognize revenue under Topic 606 for each of our performance obligations either over time (generally, the transfer of a service) or at a point in time (generally, the transfer of a good) as follows:

 

 

·

VasoTechnology

 

 

 

 

 

Revenue relating to recurring managed network and voice services provided by NetWolves are recognized as provided on a monthly basis (“over time”). Non-recurring charges related to the provision of such services are recognized in the period provided (“point in time”). In the IT VAR business, software system installations are recognized upon verification of installation and expiration of an acceptance period (“point in time”). Monthly post-implementation customer support provided under such installations as well as software solutions offered under a monthly Software as a Service (“SaaS”) fee basis are recognized monthly over the contract term (“over time”).

 

 

 

 

·

VasoHealthcare

 

 

 

 

 

Commission revenue is recognized when the underlying equipment has been delivered by GEHC and accepted at the customer site in accordance with the terms of the specific sales agreement (“point in time”).

 

 

 

 

·

VasoMedical

 

 

 

 

 

In the United States, we recognized revenue from the sale of our medical equipment in the period in which we deliver the product to the customer (“point in time”). Revenue from the sale of our medical equipment to international markets is recognized upon shipment of the product to a common carrier, as are supplies, accessories and spare parts delivered in both domestic and international markets (“point in time”). The Company also recognizes revenue from the maintenance of its medical products either on a time and material as-billed basis (“point in time”) or through the sale of a service contract, where revenue is recognized ratably over the contract term (“over time”).

 

 
F-12

Table of Contents

 

Vaso Corporation and Subsidiaries

 

 NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

 

For the Years Ended December 31, 2022 and 2021

 

 

Disaggregation of Revenue

 

The following tables present revenues disaggregated by our business operations and timing of revenue recognition:

 

 

 

Year Ended December 31, 2022

 

 

Year Ended December 31, 2021

 

 

 

 

 

 

Professional

 

 

 

 

 

 

 

 

 

 

 

Professional

 

 

 

 

 

 

 

 

 

 

 

sales

 

 

 

 

 

 

 

 

sales

 

 

 

 

 

 

 

 

 

 

service

 

 

Equipment

 

 

 

 

 

 

 

 

service

 

 

Equipment

 

 

 

 

 

 

IT segment

 

 

segment

 

 

segment

 

 

Total

 

 

IT segment

 

 

segment

 

 

segment

 

 

Total

 

Network services

 

$35,833

 

 

$-

 

 

$-

 

 

$35,833

 

 

$37,861

 

 

$-

 

 

$-

 

 

$37,861

 

Software sales and support

 

 

4,267

 

 

 

-

 

 

 

-

 

 

 

4,267

 

 

 

5,055

 

 

 

-

 

 

 

-

 

 

 

5,055

 

Commissions

 

 

-

 

 

 

37,344

 

 

 

-

 

 

 

37,344

 

 

 

-

 

 

 

29,441

 

 

 

-

 

 

 

29,441

 

Medical equipment sales

 

 

-

 

 

 

-

 

 

 

2,450

 

 

 

2,450

 

 

 

-

 

 

 

-

 

 

 

3,093

 

 

 

3,093

 

Medical equipment service

 

 

-

 

 

 

-

 

 

 

123

 

 

 

123

 

 

 

-

 

 

 

-

 

 

 

129

 

 

 

129

 

 

 

$40,100

 

 

$37,344

 

 

$2,573

 

 

$80,017

 

 

$42,916

 

 

$29,441

 

 

$3,222

 

 

$75,579

 

 

 

 

Year Ended December 31, 2022

 

 

Year Ended December 31, 2021

 

 

 

 

 

 

Professional

 

 

 

 

 

 

 

 

 

 

 

Professional

 

 

 

 

 

 

 

 

 

 

 

sales

 

 

 

 

 

 

 

 

sales

 

 

 

 

 

 

 

 

 

 

service

 

 

Equipment

 

 

 

 

 

 

 

 

service

 

 

Equipment

 

 

 

 

 

 

IT segment

 

 

segment

 

 

segment

 

 

Total

 

 

IT segment

 

 

segment

 

 

segment

 

 

Total

 

Revenue recognized over time

 

$37,089

 

 

$-

 

 

$325

 

 

$37,414

 

 

$38,172

 

 

$-

 

 

$199

 

 

$38,371

 

Revenue recognized at a point in time

 

 

3,011

 

 

 

37,344

 

 

 

2,248

 

 

 

42,603

 

 

 

4,744

 

 

 

29,441

 

 

 

3,023

 

 

 

37,208

 

 

 

$40,100

 

 

$37,344

 

 

$2,573

 

 

$80,017

 

 

$42,916

 

 

$29,441

 

 

$3,222

 

 

$75,579

 

 

Transaction Price Allocated to Remaining Performance Obligations

 

As of December 31, 2022, the aggregate amount of transaction price allocated to performance obligations that are unsatisfied (or partially unsatisfied) for executed contracts approximates $91 million, of which we expect to recognize revenue as follows:

 

 

 

Fiscal years of revenue recognition

 

 

 

2023

 

 

2024

 

 

2025

 

 

Thereafter

 

Unfulfilled performance obligations

 

$41,882

 

 

$14,496

 

 

$4,464

 

 

$29,697

 

 

As of December 31, 2021, the aggregate amount of transaction price allocated to performance obligations that were unsatisfied (or partially unsatisfied) for executed contracts approximated $86 million.

 

Contract Balances

  

Contract receivables include trade receivables, net and long-term receivables (recorded in Other assets in the consolidated balance sheets). Contract liabilities arise in our IT, VasoHealthcare, and VasoMedical businesses.  In our VHC IT business, payment arrangements with clients typically include an initial payment due upon contract signing and milestone-based payments based upon product delivery and go-live, as well as post go-live monthly payments for subscription and support fees. Customer payments received, or receivables recorded, in advance of go-live and customer acceptance, where applicable, are deferred as contract liabilities. Such amounts aggregated approximately $481,000 and $407,000 at December 31, 2022 and 2021, respectively, and are included in accrued expenses and other liabilities in our consolidated balance sheets. 

 

In our VasoHealthcare business, we bill a portion of commissions on the orders we booked in advance of delivery of the underlying equipment.  Such amounts aggregated approximately $30,794,000 and $24,955,000 at December 31, 2022 and 2021, respectively, and are classified in our consolidated balance sheets into current or long-term deferred revenue net of estimated commission adjustments.  In addition, we record a contract liability for amounts expected to be credited back to GEHC due to customer order reductions.  Such amounts aggregated approximately $2,577,000 and $1,518,000 at December 31, 2022 and 2021, respectively, and are included in accrued expenses and other liabilities in our consolidated balance sheets.

 

 
F-13

Table of Contents

 

Vaso Corporation and Subsidiaries

 

 NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

 

For the Years Ended December 31, 2022 and 2021 

 

In our VasoMedical business, we bill amounts for post-delivery services and varying duration service contracts in advance of performance.  Such amounts aggregated approximately $9,000 at December 31, 2022 and 2021, and are classified in our consolidated balance sheets as either current or long-term deferred revenue.

 

The following table summarizes the Company’s contract receivable and contract liability balances:

 

 

 

2022

 

 

2021

 

Contract receivables - January 1

 

 

15,761

 

 

 

10,200

 

Contract receivables - December 31

 

 

16,316

 

 

 

15,761

 

Increase (decrease)

 

 

555

 

 

 

5,561

 

 

 

 

 

 

 

 

 

 

Contract liabilities - January 1

 

 

26,890

 

 

 

19,375

 

Contract liabilities - December 31

 

 

33,861

 

 

 

26,890

 

Increase (decrease)

 

 

6,971

 

 

 

7,515

 

 

The increase in contract liabilities is due primarily to order bookings exceeding deliveries in our VasoHealthcare business.  During the years ended December 31, 2022 and 2021, we recognized approximately $9.1 million and $5.8 million, respectively, of revenues that were included in our contract liability balance at the beginning of such periods.

  

Costs to Obtain or Fulfill a Contract

 

Topic 606 requires that incremental costs of obtaining a contract are recognized as an asset and amortized to expense in a pattern that matches the timing of the revenue recognition of the related contract.  We have determined the only significant incremental costs incurred to obtain contracts with customers within the scope of Topic 606 are certain sales commissions paid to associates.  In addition, the Company elected the practical expedient to recognize the incremental costs of obtaining a contract when incurred for contracts where the amortization period for the asset the Company would otherwise have recognized is one year or less. 

 

Under Topic 606, sales commissions applicable to service contracts exceeding one year have been capitalized and amortized ratably over the term of the contract.  In our VHC IT business, commissions allocable to multi-year subscription contracts or multi-year post-contract support performance obligations are amortized to expense ratably over the terms of the multi-year periods.  VHC IT commissions allocable to other elements are charged to expense at go-live or customer acceptance.  In our professional sales services segment, commissions paid to our sales force are deferred until the underlying equipment is accepted by the customer.  We recognized approximately $2,732,000 and $1,928,000 of amortization related to these sales commission assets in “Cost of professional sales services” in 2022 and 2021, respectively, and approximately $79,000 and $120,000 of amortization in “Selling, general and administrative” expense in 2022 and 2021, respectively, in our consolidated statements of operations and comprehensive income.

  

At December 31, 2022 and 2021, our consolidated balance sheets include approximately $7,113,000 and $5,567,000, respectively, in capitalized sales commissions - primarily in our professional sales services segment - to be expensed in future periods, of which $3,249,000 and $3,549,000, respectively, is recorded in deferred commission expense and $3,864,000 and $2,018,000, respectively, representing the long-term portion, is included in other assets.

 

Significant Judgments when Applying Topic 606

 

Contract transaction price is allocated to performance obligations using estimated stand-alone selling price. Judgment is required in estimating stand-alone selling price for each distinct performance obligation. We determine stand-alone selling price maximizing observable inputs such as stand-alone sales when they exist or substantive renewal price charged to clients. In instances where stand-alone selling price is not observable, we utilize an estimate of stand-alone selling price based on historical pricing and industry practices.

 

Certain revenue we record in our professional sales service segment contains an estimate for variable consideration.  Due to the tiered structure of our commission rate, which increases as annual targets are achieved, under Topic 606 we record revenue and deferred revenue at the rate we expect to be achieved by year end.  We base our estimate of variable consideration on historical results of previous years’ achievement under the GEHC agreement.  Such estimate is reviewed each quarter and adjusted as necessary.  In addition, the Company records commissions for arranging financing at an estimated rate which is subject to later revision based on certain factors.  The Company recognized (decreases) increases in revenue associated with revisions to variable consideration for previously completed performance obligations of $(5,000) and $40,000 for the years ended December 31, 2022 and 2021 respectively. 

 

The Company also records commission adjustments to contract liabilities in its professional sales service segment based on estimates of future order cancellations.  Such cancellations also result in adjustments to the related capitalized cost to obtain or fulfill a contract.

 

Shipping and Handling Costs

 

All shipping and handling expenses are charged to cost of sales.  Amounts billed to customers related to shipping and handling costs are included as a component of sales.

 

 
F-14

Table of Contents

 

Vaso Corporation and Subsidiaries

 

 NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

 

For the Years Ended December 31, 2022 and 2021

 

 

Research and Development

 

Research and development costs attributable to development are expensed as incurred.

 

Share-Based Compensation

 

The Company complies with ASC Topic 718, “Compensation – Stock Compensation” (“ASC 718”), which requires all companies to recognize the cost of services received in exchange for equity instruments to be recognized in the financial statements based on their grant date fair values.  The Company applies an estimated forfeiture rate to the grant date fair value to determine the annual compensation cost of share-based payment arrangements with employees.  The forfeiture rate is estimated based primarily on job title and prior forfeiture experience.   The Company did not grant any awards to non-employees during the years ended December 31, 2022 and 2021.

 

During the year ended December 31, 2022, the Company granted 1,050,000 restricted shares of common stock valued at $115,000 to employees.  The shares vest over three and five years from the grant date.  The total fair value of shares vested during the year ended December 31, 2022 was $23,000 for officers and $4,000 for employees.  The weighted average grant date fair value of shares granted during the year ended December 31, 2022 was $0.11 per share, based on the closing price as of the grant date.

 

During the year ended December 31, 2021, the Company granted 90,000 restricted shares of common stock valued at $4,500 to an employee.  The shares vest over three years from the grant date.  The total fair value of shares vested during the year ended December 31, 2021 was $23,000 for officers and $14,000 for employees.  The weighted average grant date fair value of shares granted during the year ended December 31, 2021 was $0.05 per share.

 

The Company did not grant any stock options during the years ended December 31, 2022 or 2021, nor were any options exercised during such periods.  No options were outstanding at December 31, 2022 or 2021.

 

Share-based compensation expense recognized for the years ended December 31, 2022 and 2021 was $35,000 and $31,000, respectively, and is recorded in selling, general, and administrative expense in the consolidated statements of operations and comprehensive income.  Unrecognized expense related to existing share-based compensation and arrangements is approximately $125,000 at December 31, 2022 and will be recognized over a weighted-average period of approximately 54 months.

 

Cash and Cash Equivalents

 

Cash and cash equivalents represent cash and short-term, highly liquid investments either in certificates of deposit, treasury bills, money market funds, or investment grade commercial paper issued by major corporations and financial institutions that generally have maturities of three months or less from the date of acquisition. 

 

Short term investments

 

The Company’s short-term investments consist of six-month U.S. Treasury bills and bank deposits with yields based on underlying debt and equity securities.  The U.S. Treasury bills are classified as held-to-maturity and are carried at amortized cost of approximately $8,071,000 at December 31, 2022.  Their fair value at December 31, 2022 is approximately $8,064,000 and the unrecognized holding loss is $7,000 for the year ended December 31, 2022.  The bank deposits are carried at fair value of approximately $433,000 at December 31, 2022 and are classified as available-for-sale.  Realized gains or losses on the bank deposits are included in net income.  The Company does not expect a credit loss for its short-term investments.

 

 
F-15

Table of Contents

 

Vaso Corporation and Subsidiaries

 

 NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

 

For the Years Ended December 31, 2022 and 2021

 

 

Financial Instruments

 

The Company complies with the provisions of ASC 820 “Fair Value Measurements and Disclosures” (“ASC 820”).  Under ASC 820, fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (i.e., the “exit price”) in an orderly transaction between market participants at the measurement date.

 

In determining fair value, the Company uses various valuation approaches.  ASC 820 establishes a fair value hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available.  Observable inputs are those that market participants would use in pricing the asset or liability based on market data obtained from sources independent of the Company.  Unobservable inputs reflect the Company’s assumptions about the inputs market participants would use in pricing the asset or liability developed based on the best information available in the circumstances.  The fair value hierarchy is categorized into three levels based on the inputs as follows:

 

Level 1

 

Level 1 applies to assets or liabilities for which there are quoted prices in active markets for identical assets or liabilities.

 

Level 2

 

Level 2 applies to assets or liabilities for which there are inputs other than quoted prices that are observable for the asset or liability such as quoted prices for similar assets or liabilities in active markets; quoted prices for identical assets or liabilities in markets with insufficient volume or infrequent transactions (less active markets); or model-derived valuations in which significant inputs are observable or can be derived principally from, or corroborated by, observable market data.

 

Level 3

 

Level 3 applies to assets or liabilities for which there are unobservable inputs to the valuation methodology that are significant to the measurement of the fair value of the assets or liabilities.

 

The carrying amount of assets and liabilities including cash and cash equivalents, short-term investments, accounts receivable, prepaids, accounts payable, accrued expenses and other current liabilities approximated their fair value as of December 31, 2022 and 2021, due to the relative short maturity of these instruments. Property and equipment, intangible assets, capital lease obligations, and goodwill are not required to be re-measured to fair value on a recurring basis. These assets are evaluated for impairment if certain triggering events occur. If such evaluation indicates that impairment exists, the respective asset is written down to its fair value.

 

 
F-16

Table of Contents

 

Vaso Corporation and Subsidiaries

 

 NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

 

For the Years Ended December 31, 2022 and 2021

 

The following table presents information about the Company’s assets measured at fair value as of December 31, 2022 and 2021:

 

 

 

 

Quoted Prices

 

 

Significant

 

 

 

 

 

 

 

 

in Active

 

 

Other

 

 

Significant

 

 

Balance

 

 

 

Markets for

 

 

Observable

 

 

Unobservable

 

 

as of

 

 

 

Identical Assets

 

 

Inputs

 

 

Inputs

 

 

December 31,

 

 

 

(Level 1)

 

 

(Level 2)

 

 

(Level 3)

 

 

2022

 

Assets

 

 

 

 

 

 

 

 

 

 

 

 

Cash equivalents invested in money market funds

 

$7,934

 

 

$-

 

 

$-

 

 

$7,934

 

Bank deposits (included in short term investments)

 

 

433

 

 

 

 

 

 

 

 

 

 

 

433

 

 

 

$8,367

 

 

$-

 

 

$-

 

 

$8,367

 

 

 

 

Quoted Prices

 

 

Significant

 

 

 

 

 

 

 

in Active

 

 

Other

 

 

Significant

 

 

Balance

 

 

 

Markets for

 

 

Observable

 

 

Unobservable

 

 

as of

 

 

 

Identical Assets

 

 

Inputs

 

 

Inputs

 

 

December 31,

 

 

 

(Level 1)

 

 

(Level 2)

 

 

(Level 3)

 

 

2021

 

Assets

 

 

 

 

 

 

 

 

 

 

 

 

Cash equivalents invested in money market funds

 

$802

 

 

$-

 

 

$-

 

 

$802

 

Bank deposits (included in short term investments)

 

 

629

 

 

 

 

 

 

 

 

 

 

 

629

 

 

 

$1,431

 

 

$-

 

 

$-

 

 

$1,431

 

 

Accounts Receivable, net

 

The Company’s accounts receivable are due from customers to whom we sell our products and services, distributors engaged in the distribution of our products and from GEHC. Credit is extended based on evaluation of a customer’s financial condition and, generally, collateral is not required. Accounts receivable are generally due 30 to 90 days from shipment and services provided and are stated at amounts due from customers net of allowances for doubtful accounts, returns, term discounts and other allowances. Accounts that are outstanding longer than the contractual payment terms are considered past due. Estimates are used in determining the allowance for doubtful accounts based on the Company’s historical collections experience, current trends, credit policy and a percentage of its accounts receivable by aging category. In determining these percentages, the Company reviews historical write-offs of their receivables. The Company also looks at the credit quality of their customer base as well as changes in their credit policies. The Company continuously monitors collections and payments from our customers, and writes off receivables when all efforts at collection have been exhausted. While credit losses have historically been within expectations and the provisions established, the Company cannot guarantee that it will continue to experience the same credit loss rates that they have in the past.   

 

The changes in the Company’s allowance for doubtful accounts and commission adjustments are as follows:

 

 

 

(in thousands)

Year ended December 31,

 

 

 

2022

 

 

2021

 

Beginning Balance

 

$5,804

 

 

$4,208

 

Provision for losses on accounts receivable

 

 

63

 

 

 

132

 

Direct write-offs, net of recoveries

 

 

(159)

 

 

(77)

Commission adjustments

 

 

1,239

 

 

 

1,541

 

Ending Balance

 

$6,947

 

 

$5,804

 

 

 
F-17

Table of Contents

 

Vaso Corporation and Subsidiaries

 

 NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

 

For the Years Ended December 31, 2022 and 2021 

 

 

Concentrations of Credit Risk

 

We market our equipment and IT software solutions principally to hospitals, diagnostic imaging centers and physician private practices. We perform credit evaluations of our customers’ financial condition and, as a result, believe that our receivable credit risk exposure is limited.  For the years ended December 31, 2022 and 2021, no customer in our equipment or IT segment accounted for 10% or more of revenues or accounts receivable.  In our professional sales service segment, 100% of our revenues and accounts receivable are with GEHC; however, we believe this risk is acceptable based on GEHC’s financial position and our long history of doing business with GEHC. 

 

The Company maintains cash balances in certain U.S. financial institutions, which, at times, may exceed the Federal Depository Insurance Corporation (“FDIC”) coverage of $250,000.  The Company has not experienced any losses on these accounts and believes it is not subject to any significant credit risk on these accounts.  In addition, the FDIC does not insure the Company’s foreign bank balances, which aggregated approximately $1,234,000 and $903,000 at December 31, 2022 and 2021, respectively.

 

Inventories

 

The Company values inventories in the equipment segment at the lower of cost or net realizable value, with cost being determined on a first-in, first-out basis. The Company regularly reviews inventory quantities on hand, particularly raw materials and components, and records a provision for excess and slow moving inventory based primarily on existing and anticipated design and engineering changes to its products as well as forecasts of future product demand.

 

In our IT Segment, we purchase computer hardware and software for specific customer requirements and value such inventories using the specific identification method.

 

Property and Equipment

 

Property and equipment, including assets under finance leases, are stated at cost less accumulated depreciation and amortization. Major improvements are capitalized and minor replacements, maintenance and repairs are charged to expense as incurred. Upon retirement or disposal of assets, the cost and related accumulated depreciation are removed from the consolidated balance sheets. Depreciation is expensed over the estimated useful lives of the assets, which range from two to eight years, on a straight-line basis. Accelerated methods of depreciation are used for tax purposes. We amortize leasehold improvements over the useful life of the related leasehold improvement or the life of the related lease, whichever is less.

 

Impairment of Long-lived Assets

 

The Company reviews the recoverability of all long-lived assets, including the related useful lives, whenever events or changes in circumstances indicate that the carrying amount of a long-lived asset might not be recoverable. If required, the Company compares the estimated fair value determined by either the undiscounted future net cash flows or appraised value to the related asset’s carrying value to determine whether there has been an impairment. If an asset is considered impaired, the asset is written down to fair value, which is based either on discounted cash flows or appraised values in the period the impairment becomes known.  In December 2021, the Company deemed $324,000 in long-lived assets to be impaired.  The impairment loss is reflected in cost of managed IT systems and services in the Company’s consolidated statement of operations.  No assets were determined to be impaired as of December 31, 2022.

 

Goodwill and Intangible Assets

 

Goodwill represents the excess of cost over the fair value of net assets of businesses acquired. The Company accounts for goodwill under the guidance of the ASC Topic 350, “Intangibles: Goodwill and Other”. Goodwill acquired in a purchase business combination is not amortized, but instead tested for impairment, at least annually, in accordance with this guidance.  The recoverability of goodwill is subject to an annual impairment test or whenever an event occurs or circumstances change that would more likely than not result in an impairment. The Company tests goodwill for impairment at the reporting unit level on an annual basis as of December 31 and between annual tests when an event occurs or circumstances change that could indicate that the asset might be impaired. In any year, the Company may elect to perform a qualitative assessment to determine whether it is more likely than not that the fair value of a reporting unit is in excess of its carrying value.  If the Company cannot determine qualitatively that the fair value is in excess of the carrying value, or the Company decides to bypass the qualitative assessment, the Company proceeds to the quantitative goodwill impairment test, which compares the fair value of each reporting unit to its carrying amount, including goodwill. If the fair value of each reporting unit exceeds its carrying amount, goodwill is not considered to be impaired. If the carrying amount of a reporting unit exceeds its fair value, an impairment loss is recognized for an amount equal to that excess, limited to the total amount of goodwill allocated to that reporting unit. No goodwill was determined to be impaired as of December 31, 2022 and 2021.

 

 
F-18

Table of Contents

 

Vaso Corporation and Subsidiaries

 

 NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

 

For the Years Ended December 31, 2022 and 2021

 

Intangible assets consist of the value of customer contracts and relationships, patent and technology costs, and software. The cost of significant customer-related intangibles is amortized in proportion to estimated total related revenue; cost of other intangible assets is generally amortized on a straight-line basis over the asset’s estimated economic life, which range from five to ten years. The Company capitalizes internal use software development costs incurred during the application development stage. Costs related to preliminary project activities, training, data conversion, and post implementation activities are expensed as incurred. The Company did not capitalize any software development costs for the years ended December 31, 2022 and 2021. In December 2021, the Company deemed $1.1 million in capitalized software costs to be impaired.  The impairment loss is reflected in R&D expenses in the Company’s consolidated statement of operations.  No intangible assets were determined to be impaired as of December 31, 2022.

 

Deferred Revenue

 

Amounts billable under the agreement with GEHC in advance of delivery of the underlying equipment are recorded initially as deferred revenue, and commission revenue is subsequently recognized as customer acceptance of such equipment is reported to us by GEHC. Similarly, commissions payable to our sales force related to such billings are recorded as deferred commission expense when the associated deferred revenue is recorded. Commission expense is recognized when the corresponding commission revenue is recognized.

 

In our equipment segment, we record revenue on extended service contracts ratably over the term of the related service contracts. 

 

Income Taxes

 

Deferred income taxes are recognized for temporary differences between financial statement and income tax bases of assets and liabilities and loss carry-forwards for which income tax benefits are expected to be realized in future years. A valuation allowance is established, when necessary, to reduce deferred tax assets to the amount expected to be realized. In estimating future tax consequences, we generally consider all expected future events other than an enactment of changes in the tax laws or rates. Deferred tax assets are continually evaluated for the expected realization. To the extent our judgment regarding the realization of the deferred tax assets changes, an adjustment to the allowance is recorded, with an offsetting increase or decrease, as appropriate, in income tax expense. Such adjustments are recorded in the period in which our estimate as to the realization of the assets changed that it is “more likely than not” that all of the deferred tax assets will be realized. The “realization” standard is subjective and is based upon our estimate of a greater than 50% probability that the deferred tax asset can be realized.

 

The Company also complies with the provisions of ASC Topic 740, “Income Taxes”, which prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more-likely-than-not to be sustained upon examination by the relevant taxing authority based on the technical merits.  The tax benefit recognized is measured as the largest amount of benefit that has a greater than fifty percent likelihood of being realized upon ultimate settlement with the relevant taxing authority.  Derecognition of a tax benefit previously recognized results in the Company recording a tax liability that reduces ending retained earnings.  Based on its analysis, the Company has determined that it has not incurred any liability for unrecognized tax benefits as of December 31, 2022 and 2021.  The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense.  No amounts were accrued for the payment of interest and penalties at December 31, 2022 and 2021.  Generally, the Company is no longer subject to income tax examinations by major domestic taxing authorities for years before 2019.  According to the China tax regulatory framework, there is no statute of limitations on examination of tax filings by tax authorities.  However, the general practice is going back five years.  Management is currently unaware of any issues under review that could result in significant payments, accruals or material deviations from its position. 

 

 
F-19

Table of Contents

 

Vaso Corporation and Subsidiaries

 

 NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

 

For the Years Ended December 31, 2022 and 2021 

 

 

Foreign Currency Translation Gain (Loss) and Comprehensive Income

  

In the country in which the Company operates, and the functional currency is other than the U.S. dollar, assets and liabilities are translated using published exchange rates in effect at the consolidated balance sheet date.  Equity accounts are translated at historical rates except for the changes in accumulated deficit during the year as the result of the income statement translation process.  Revenues and expenses and cash flows are translated using a weighted average exchange rate for the period.  Resulting translation adjustments are recorded as a component of accumulated other comprehensive income (loss) on the accompanying consolidated balance sheets.  For the years ended December 31, 2022 and 2021, other comprehensive income (loss) includes (losses) gains of $(343,000) and $94,000, respectively, which were entirely from foreign currency translation.

 

Net Income Per Common Share

 

Basic income per common share is based on the weighted average number of common shares outstanding, including vested restricted shares, without consideration of potential common stock. Diluted earnings per common share is based on the weighted average number of common and potential dilutive common shares outstanding. 

 

Diluted earnings per share were computed based on the weighted average number of shares outstanding plus all potentially dilutive common shares.  A reconciliation of basic to diluted shares used in the earnings per share calculation is as follows:

 

 

 

(in thousands)

Year ended December 31,

 

 

 

2022

 

 

2021

 

 

 

 

 

 

 

 

Basic weighted average shares outstanding

 

 

173,065

 

 

 

171,688

 

Dilutive effect of unvested restricted shares

 

 

1,591

 

 

 

2,083

 

Diluted weighted average shares outstanding

 

 

174,656

 

 

 

173,771

 

 

No common stock equivalents were excluded from the computation of diluted earnings per share for the years ended December 31, 2022 and 2021. 

  

Recently Adopted Accounting Pronouncements

  

New pronouncements adopted by the Company recently are discussed below:

 

Credit Losses on Financial instruments

 

In June 2016, the FASB issued ASU 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, which provides new guidance regarding the measurement and recognition of credit impairment for certain financial assets. Such guidance will impact how we determine our allowance for estimated uncollectible receivables. In April 2019, the FASB issued ASU 2019-04, Codification Improvements to Topic 326, Financial Instruments - Credit Losses, Topic 825, Derivatives and Hedging, and Topic 825, Financial Instruments, which provided various amendments to these Topics.  In November 2019, the FASB issued ASU 2019-10, which changed the effective date of ASU 2016-13 and ASU 2019-04 for smaller reporting companies as defined by the SEC from first quarter of 2020 to the first quarter of 2023, with early adoption permitted.

  

The Company early adopted ASU 2016-13 and ASU 2019-04 effective October 1, 2022.  ASU 2016-13 added a current expected credit loss impairment model to U.S. GAAP based on expected losses rather than incurred losses. The adoption of this standard did not result in any material impact to our allowance for doubtful accounts balance as of October 1, 2022. As a result of adoption, the Corporation will utilize current and historical collection data as well as assess current economic conditions in order to determine expected trade credit losses on a prospective basis.  ASU 2019-04 provided additional guidance on disclosure of credit losses on accrued interest receivables on held-to-maturity debt securities and additional disclosure requirements for such securities to include fair value and unrecognized gains and losses.  Because the Company’s sole investments of held-to-maturity debt securities are six-month U.S. Treasury bills, no provision for credit losses on such securities was deemed necessary, and the applicable fair value and unrecognized gains and losses were included in the above Short Term Investment section of Note B.  

 

Recently Issued Accounting Pronouncements

 

The Company continually assesses any new accounting pronouncements to determine their applicability to the Company. Where it is determined that a new accounting pronouncement affects the Company’s financial reporting, the Company undertakes a study to determine the consequence of the change to its financial statements and assures that there are proper controls in place to ascertain that the Company’s consolidated financial statements properly reflect the change. New pronouncements assessed by the Company recently are discussed below:

 

In September 2022, the FASB issued ASU No. 2022-04, Liabilities — Supplier Finance Programs (Subtopic 405-50): Disclosure of Supplier Finance Program Obligations. This ASU requires that a buyer in a supplier finance program disclose the key terms of supplier finance programs, the amount of obligations outstanding at the end of the reporting period that the entity has confirmed as valid to the finance provider, where these obligations are recorded in the balance sheet, and a roll forward of the obligations. The new standard is effective for fiscal years beginning after December 15, 2022, on a retrospective basis, including interim periods within those fiscal years. The Company is currently evaluating the impact that adopting this standard will have on the consolidated financial statements.

 

In October 2021, the FASB issued ASU No. 2021-08, Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers. The ASU amends ASC 805 to add contract assets and contract liabilities to the list of exceptions to the recognition and measurement principles that apply to business combinations and to require that an entity (acquirer) recognize and measure contract assets and contract liabilities acquired in a business combination in accordance with Topic 606. While primarily related to contract assets and contract liabilities that were accounted for by the acquiree in accordance with ASC 606, the amendments also apply to contract assets and contract liabilities from other contracts to which the provisions of Topic 606 apply, such as contract liabilities from the sale of nonfinancial assets within the scope of Subtopic 610-20. The ASU should be applied prospectively and is effective for the Company for fiscal years beginning after December 15, 2023, and interim periods within those fiscal years. Early adoption is permitted. The Company is currently evaluating the impact that adopting this standard will have on the consolidated financial statements.

 

 
F-20

Table of Contents

 

Vaso Corporation and Subsidiaries

 

 NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

 

For the Years Ended December 31, 2022 and 2021 

 

NOTE C – SEGMENT REPORTING

 

The Company views its business in three segments – the IT segment, the professional sales service segment, and the equipment segment.  The IT segment includes the operations of NetWolves and VasoHealthcare IT Corp.  The professional sales service segment operates through the VasoHealthcare subsidiary and is currently engaged solely in the fulfillment of the Company’s responsibilities under our agreement with GEHC.  The equipment segment is engaged in designing, manufacturing, marketing and supporting of proprietary medical devices and software, as well as managing the domestic business of EECP® enhanced external counterpulsation per a management service agreement with EECP Global.    

 

The chief operating decision maker is the Company’s Chief Executive Officer, who, in conjunction with upper management, evaluates segment performance based on operating income and Adjusted EBITDA (earnings before interest, taxes, depreciation and amortization – defined as net (loss) income, plus net interest expense (income), tax expense, depreciation and amortization, and non-cash expenses for share-based compensation).  Administrative functions such as finance and human resources are centralized and related expenses allocated to each segment.  Other costs not directly attributable to operating segments, such as audit, legal, director fees, investor relations, and others, as well as certain assets – primarily cash balances – are reported in the Corporate entity below.  There are no intersegment revenues.  Summary financial information for the segments is set forth below:

  

 

 

(in thousands)

Year ended December 31,

 

 

 

2022

 

 

2021

 

 

 

 

 

 

 

 

Revenues from external customers

 

 

 

 

 

 

IT

 

$40,100

 

 

$42,916

 

Professional sales service

 

 

37,344

 

 

 

29,441

 

Equipment

 

 

2,573

 

 

 

3,222

 

Total revenues

 

$80,017

 

 

$75,579

 

 

 

 

 

 

 

 

 

 

Gross Profit

 

 

 

 

 

 

 

 

IT

 

$16,229

 

 

$16,674

 

Professional sales service

 

 

30,288

 

 

 

23,906

 

Equipment

 

 

1,964

 

 

 

2,553

 

Total gross profit

 

$48,481

 

 

$43,133

 

 

 

 

 

 

 

 

 

 

Operating income (loss)

 

 

 

 

 

 

 

 

IT

 

$(1,620)

 

$(2,062)

Professional sales service

 

 

10,099

 

 

 

5,918

 

Equipment

 

 

(180)

 

 

32

 

Corporate

 

 

(1,266)

 

 

(1,069)

Total operating income

 

$7,033

 

 

$2,819

 

 

 

 

 

 

 

 

 

 

Depreciation and amortization

 

 

 

 

 

 

 

 

IT

 

$1,692

 

 

$3,394

 

Professional sales service

 

 

33

 

 

 

153

 

Equipment

 

 

198

 

 

 

293

 

Corporate

 

 

-

 

 

 

-

 

Total depreciation and amortization

 

$1,923

 

 

$3,840

 

 

 

 

 

 

 

 

 

 

Capital expenditures

 

 

 

 

 

 

 

 

IT

 

$406

 

 

$334

 

Professional sales service

 

 

125

 

 

 

41

 

Equipment

 

 

34

 

 

 

37

 

Corporate

 

 

1

 

 

 

3

 

Total cash capital expenditures

 

$566

 

 

$415

 

 

 
F-21

Table of Contents

 

Vaso Corporation and Subsidiaries

 

 NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

 

For the Years Ended December 31, 2022 and 2021 

 

 

 

December 31, 2022

 

 

December 31, 2021

 

 

 

 

 

 

 

 

Identifiable Assets

 

 

 

 

 

 

IT

 

$22,201

 

 

$23,144

 

Professional sales service

 

 

21,684

 

 

 

18,718

 

Equipment

 

 

6,957

 

 

 

7,144

 

Corporate

 

 

21,813

 

 

 

3,355

 

Total assets

 

$72,655

 

 

$52,361

 

 

For the years ended December 31, 2022 and 2021, GEHC accounted for 47% and 39% of revenue, respectively.  Also, GEHC accounted for $12.8 million, or 83%, and $12.3 million, or 80%, of accounts and other receivables at December 31, 2022 and 2021, respectively.

 

Our revenues were derived from the following geographic areas:

 

 

 

(in thousands)

Year ended December 31,

 

 

 

2022

 

 

2021

 

Domestic (United States)

 

$77,785

 

 

$72,681

 

Non-domestic (foreign)

 

 

2,232

 

 

 

2,898

 

 

 

$80,017

 

 

$75,579

 

 

NOTE D – ACCOUNTS AND OTHER RECEIVABLES

 

The following table presents information regarding the Company’s accounts and other receivables as of December 31, 2022 and 2021:

 

 

 

(in thousands)

 

 

 

December 31, 2022

 

 

December 31, 2021

 

 

 

 

 

 

 

 

Trade receivables

 

$22,471

 

 

$21,197

 

Allowance for doubtful accounts and

 

 

 

 

 

 

 

 

commission adjustments

 

 

(6,947)

 

 

(5,804)
Accounts and other receivables, net

 

$15,524

 

 

$15,393

 

 

 

Trade receivables include amounts due for shipped products and services rendered.  Amounts currently due under the GEHC Agreement are subject to adjustment in subsequent periods should the underlying sales order amount, upon which the receivable is based, change.

 

Allowance for doubtful accounts and commission adjustments include estimated losses resulting from the inability of our customers to make required payments, and adjustments arising from estimated future changes in sales order amounts that may reduce the amount the Company will ultimately receive under the GEHC Agreement.

 

NOTE E – INVENTORIES

 

Inventories, net of reserves, consisted of the following:

 

 

 

(in thousands)

 

 

 

December 31, 2022

 

 

December 31, 2021

 

 

 

 

 

 

 

 

Raw materials

 

$751

 

 

$744

 

Work in process

 

 

6

 

 

 

4

 

Finished goods

 

 

716

 

 

 

399

 

 

 

$1,473

 

 

$1,147

 

 

At December 31, 2022 and 2021, the Company maintained reserves for slow moving inventories of $163,000 and $165,000, respectively.

 

 
F-22

Table of Contents

 

Vaso Corporation and Subsidiaries

 

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

 

For the Years Ended December 31, 2022 and 2021

 

NOTE F – PROPERTY AND EQUIPMENT

 

Property and equipment is summarized as follows:

 

 

 

(in thousands)

 

 

 

December 31, 2022

 

 

December 31, 2021

 

 

 

 

 

 

 

 

Office, laboratory and other equipment

 

$1,928

 

 

$1,940

 

Equipment furnished for customer or clinical uses

 

 

7,981

 

 

 

9,359

 

Right of use assets - finance leases

 

 

1,119

 

 

 

1,286

 

Furniture and fixtures

 

 

99

 

 

 

99

 

 

 

 

11,127

 

 

 

12,684

 

Less: accumulated depreciation and amortization

 

 

(9,787)

 

 

(10,512)

Property and equipment, net

 

$1,340

 

 

$2,172

 

 

 

Accumulated amortization of right of use (“ROU”) assets under finance leases aggregated approximately $858,000 and $833,000 at December 31, 2022 and 2021, respectively.  Depreciation expense amounted to approximately $1,372,000 and $1,868,000 for the years ended December 31, 2022 and 2021, respectively.  Amortization of ROU assets under finance leases is included in depreciation expense.

 

NOTE G – GOODWILL AND OTHER INTANGIBLES

 

Goodwill of $14,375,000 is attributable to the NetWolves reporting unit within the IT segment.  The remaining $1,239,000 of goodwill is attributable to the FGE reporting unit within the Equipment segment.  The NetWolves and FGE reporting units had negative net asset carrying amounts at December 31, 2022 and 2021.  The changes in the carrying amount of goodwill are as follows:

 

 

 

(in thousands)

 

 

 

Year ended

 

 

Year ended

 

 

 

December 31, 2022

 

 

December 31, 2021

 

 

 

 

 

 

 

 

Beginning of period

 

$15,722

 

 

$15,688

 

Foreign currency translation adjustment

 

 

(108)

 

 

34

 

End of period

 

$15,614

 

 

$15,722

 

 

 
F-23

Table of Contents

 

Vaso Corporation and Subsidiaries

 

 NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

 

For the Years Ended December 31, 2022 and 2021 

 

The Company’s other intangible assets consist of capitalized customer-related intangibles, patent and technology costs, and software costs, as set forth in the following table:

 

 

 

 

(in thousands)

 

 

 

December 31, 2022

 

 

December 31, 2021

 

 

 

 

 

 

 

 

Customer-related

 

 

 

 

 

 

Costs

 

$5,831

 

 

$5,831

 

Accumulated amortization

 

 

(4,557)

 

 

(4,279)

 

 

 

1,274

 

 

 

1,552

 

Patents and Technology

 

 

 

 

 

 

 

 

Costs

 

 

1,894

 

 

 

1,894

 

Accumulated amortization

 

 

(1,894)

 

 

(1,754)

 

 

 

-

 

 

 

140

 

Software

 

 

 

 

 

 

 

 

Costs

 

 

2,362

 

 

 

3,459

 

Accumulated amortization

 

 

(2,125)

 

 

(3,110)

 

 

 

237

 

 

 

349

 

 

 

 

 

 

 

 

 

 

 

 

$1,511

 

 

$2,041

 

 

The Company owns, through our Chinese subsidiaries, thirty-seven invention and utility patents that expire at various times through 2041, as well as sixteen software copyright certificates in China related to proprietary technologies in physiological data acquisition, analysis and reporting. The Company also holds one patent for secure and remote monitoring management through its NetWolves subsidiary.  Costs incurred for submitting the applications to the United States Patent and Trademark Office and other foreign authorities for these patents have been capitalized.  Patent and technology costs are being amortized using the straight-line method over 10-year and 8-year lives, respectively.  The Company begins amortizing patent costs once a filing receipt is received stating the patent serial number and filing date from the Patent Office or other foreign authority.  The cost of significant customer-related intangibles is amortized in proportion to estimated total related revenue; cost of other customer-related intangible assets is amortized on a straight-line basis over the asset’s estimated economic life of seven years. Software costs are amortized on a straight-line basis over its expected useful life of five years. In 2022, the Company disposed of approximately $1,117,000 in fully amortized software costs.

 

Amortization expense amounted to approximately $551,000 and $1,972,000 for the years ended December 31, 2022 and 2021, respectively.  Amortization of intangibles for the next five years is:

 

 

 

(in thousands)

 

Years ending December 31,

 

 

 

2023

 

 

343

 

2024

 

 

274

 

2025

 

 

203

 

2026

 

 

148

 

2027

 

 

543

 

 

 

$1,511

 

 

 
F-24

Table of Contents

 

Vaso Corporation and Subsidiaries

 

 NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

 

For the Years Ended December 31, 2022 and 2021 

 

NOTE H – OTHER ASSETS

 

Other assets consist of the following:

 

 

 

(in thousands)

 

 

 

December 31, 2022

 

 

December 31, 2021

 

 

 

 

 

 

 

 

Deferred commission expense - noncurrent

 

$3,864

 

 

$2,018

 

Trade receivables - noncurrent

 

 

792

 

 

 

368

 

Other, net of allowance for loss on loan receivable of $412 at December 31, 2022 and 2021

 

 

70

 

 

 

60

 

 

 

$4,726

 

 

$2,446

 

 

NOTE I – DEFERRED REVENUE

 

The changes in the Company’s deferred revenues are as follows:

 

 

 

(in thousands)

Year ended December 31,

 

 

 

2022

 

 

2021

 

 

 

 

 

 

 

 

Deferred revenue at beginning of period

 

$24,965

 

 

$17,704

 

Net additions:

 

 

 

 

 

 

 

 

Deferred extended service contracts

 

 

3

 

 

 

(1)

Deferred commission revenues

 

 

19,666

 

 

 

17,080

 

Recognized as revenue:

 

 

 

 

 

 

 

 

Deferred extended service contracts

 

 

(4)

 

 

(5)

Deferred commission revenues

 

 

(13,827)

 

 

(9,813)
Deferred revenue at end of period

 

 

30,803

 

 

 

24,965

 

Less: current portion

 

 

15,139

 

 

 

16,495

 

Long-term deferred revenue at end of period

 

$15,664

 

 

$8,470

 

 

NOTE J – ACCRUED EXPENSES AND OTHER LIABILITIES

 

Accrued expenses and other liabilities consist of the following:

 

 

 

 (in thousands)

 

 

 

December 31, 2022

 

 

December 31, 2021

 

 

 

 

 

 

 

 

Accrued compensation

 

$2,652

 

 

$2,397

 

Accrued expenses - other

 

 

2,012

 

 

 

1,799

 

Order reduction liability

 

 

 2,577

 

 

 

 1,518

 

Other liabilities

 

 

1,650

 

 

 

1,775

 

 

 

$8,891

 

 

$7,489

 

 

 
F-25

Table of Contents

 

Vaso Corporation and Subsidiaries

 

 NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

 

For the Years Ended December 31, 2022 and 2021

 

NOTE K – RELATED-PARTY TRANSACTIONS

 

The Company recorded interest charges aggregating $0 and approximately $131,000 for the years ended December 31, 2022 and 2021, respectively, payable to MedTechnology Investments, LLC (“MedTech”) pursuant to its promissory notes (“Notes”). The MedTech Notes were used in 2015 to partially fund the purchase of NetWolves. $2,300,000 of the $4,800,000 provided by MedTech was provided by directors of the Company, or by family members. The Notes were fully repaid in December 2021.

 

David Lieberman, a practicing attorney in the State of New York, serves as Vice Chairman of the Board of Directors.  Until July 2022, he was a senior partner at the law firm of Beckman Lieberman and Associates, LLP, which performed certain legal services for the Company.  Fees of approximately $95,000 and $190,000 were billed by the firm for the years ended December 31, 2022 and 2021, respectively, at which dates no amounts were outstanding.  

 

NOTE L – NOTES PAYABLE AND REVOLVING CREDIT AGREEMENT

 

                Notes payable consist of the following:

 

 

 

(in thousands)

 

 

 

December 31, 2022

 

 

December 31, 2021

 

 

 

 

 

 

 

 

Notes payable

 

 

24

 

 

 

31

 

Less: current portion

 

 

(9)

 

 

(8)

 

 

$15

 

 

$23

 

 

Notes payable consists of a vehicle loan.  The note is secured by the vehicle, bears interest at 1.9% per annum and matures in August 2025.

 

                On December 30, 2022, the Company executed a $3.0 million revolving credit agreement with a lending institution.  Advances under the agreement bear interest at Wall Street Journal Prime Rate and are secured by substantially all of the assets of the Company.  The agreement expires August 31, 2023 and includes certain financial covenants.  The Company was in compliance with such covenants at December 31, 2022, at which time no amounts had been drawn.

 

NOTE M – LEASES

 

The Company enters into finance leases, typically with terms of 3 to 5 years, to acquire equipment for its data center. The Company enters into operating leases for its facilities in New York, Florida, and China, as well as for vehicles and equipment provided to certain employees in the professional sales services segment. The operating lease terms range from 2 to 7 years. The Company excluded the renewal option on its applicable facility leases from the calculation of its right-of-use assets and lease liabilities.  The Company made the accounting policy decision not to recognize lease assets and liabilities for leases with a term of 12 months or less.

 

Finance and operating lease liabilities consist of the following:

 

 

 

 (in thousands)

 

 

 

December 31, 2022

 

 

December 31, 2021

 

 

 

 

 

 

 

 

Lease liabilities - current

 

 

 

 

 

 

Finance leases

 

$122

 

 

$222

 

Operating leases

 

 

745

 

 

 

562

 

 

 

$867

 

 

$784

 

Lease liabilities - net of current portion

 

 

 

 

 

 

 

 

Finance leases

 

$96

 

 

$218

 

Operating leases

 

 

823

 

 

 

352

 

 

 

$919

 

 

$570

 

 

 
F-26

Table of Contents

 

Vaso Corporation and Subsidiaries

 

 NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

 

For the Years Ended December 31, 2022 and 2021 

 

A reconciliation of undiscounted cash flows to finance and operating lease liabilities recognized in the consolidated balance sheet at December 31, 2022 is set forth below:

 

 

 

 

(in thousands)

 

Years ending December 31,

 

Finance leases

 

 

Operating leases

 

 

Total

 

2023

 

 

144

 

 

 

782

 

 

 

926

 

2024

 

 

83

 

 

 

554

 

 

 

637

 

2025

 

 

25

 

 

 

324

 

 

 

349

 

2026

 

 

-

 

 

 

71

 

 

 

71

 

Undiscounted lease payments

 

 

252

 

 

 

1,731

 

 

 

1,983

 

Amount representing interest

 

 

(34)

 

 

(163)

 

 

(197)

Discounted lease liabilities

 

 

218

 

 

 

1,568

 

 

 

1,786

 

 

Additional disclosures of lease data are set forth below:

 

 

 

(in thousands)

 

 

 

Year ended

December 31, 2022

 

 

Year ended

December 31, 2021

 

 

 

 

 

 

 

 

Lease costs:

 

 

 

 

 

 

Finance lease costs:

 

 

 

 

 

 

Amortization of right-of-use assets

 

$154

 

 

$193

 

Interest on lease liabilities

 

 

44

 

 

 

45

 

 

 

 

198

 

 

 

238

 

Operating lease costs

 

 

878

 

 

 

792

 

Short-term lease costs

 

 

52

 

 

 

78

 

Total lease cost

 

$1,128

 

 

$1,108

 

 

 

 

 

 

 

 

 

 

Other information:

 

 

 

 

 

 

 

 

Cash paid for amounts included in the measurement of lease liabilities:

 

 

 

 

 

 

 

 

Operating cash flows from finance leases

 

$44

 

 

$45

 

Operating cash flows from operating leases

 

 

878

 

 

 

792

 

Financing cash flows from finance leases

 

 

222

 

 

 

199

 

 

 

$1,144

 

 

$1,036

 

 

 

 

December 31, 2022

 

 

December 31, 2021

 

 

 

 

 

 

 

 

Weighted-average remaining lease term - finance leases (months)

 

 

23

 

 

 

28

 

Weighted-average remaining lease term - operating leases (months)

 

 

30

 

 

 

25

 

 

 

 

 

 

 

 

 

 

Weighted-average discount rate - finance leases

 

 

14.2%

 

 

13.1%
Weighted-average discount rate - operating leases

 

 

9.1%

 

 

8.8%

 

 
F-27

Table of Contents

 

Vaso Corporation and Subsidiaries

 

 NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

 

For the Years Ended December 31, 2022 and 2021 

 

The Company used the rate implicit in the lease, where known, or its incremental borrowing rate as the rate used to discount the future lease payments.

 

NOTE N – EQUITY IN THE EECP BUSINESS

 

On May 20, 2020, the Company closed on the sale of 51% of the capital stock of its wholly-owned subsidiary EECP Global Corporation (“EECP Global”) to Chongqing PSK-Health Sci-Tech Development Co. Ltd, a China-based company, for $1,150,000. EECP Global was formed in September 2019 to hold all the assets and liabilities of its EECP business. Concurrently with the closing of the transaction, the Company signed a Management Service Agreement with EECP Global to provide management service for the business and operation of EECP Global in the United States. The agreement provides an initial term of three years starting April 1, 2020, the effective date of the sale, which is automatically renewable for additional one-year terms. Pursuant to the agreement, EECP Global reimburses the Company all direct expenses and pays a monthly management fee during the term of the agreement.

 

The Company uses the equity method to account for its interest in EECP Global, as it has the ability to exercise significant influence over the entity, and reports its share of EECP Global operations in Other Income (Expense) on its consolidated statements of operations and comprehensive income. For the years ended December 31, 2022 and 2021, the Company’s share of EECP Global’s loss was approximately $154,000 and $73,000, respectively. At December 31, 2022 and 2021, the Company recorded Receivables due from related parties, net of approximately $403,000 and $46,000, respectively, on its consolidated balance sheets for amounts due from EECP Global for fees and cost reimbursements, net of receivables collected on its behalf due to EECP Global.

 

NOTE O – STOCKHOLDERS’ EQUITY

 

Chinese subsidiaries dividends and statutory reserves

 

The payment of dividends by entities organized in China is subject to limitations. In particular, regulations in China currently permit payment of dividends only out of accumulated profits as determined in accordance with People’s Republic of China (“PRC”) accounting standards and regulations. Based on PRC accounting standards, our Chinese subsidiaries are also required to set aside at least 10% of after-tax profit each year to their general reserves until the accumulative amount of such reserves reaches 50% of the registered capital. As of December 31, 2022 and 2021, statutory reserves aggregating approximately $35,000 were recorded in the Company’s consolidated balance sheets.  These reserves are not distributable as cash dividends. In addition, they are required to allocate a portion of their after-tax profit to their staff welfare and bonus fund at the discretion of their respective boards of directors. Moreover, if any of our PRC subsidiaries incurs debt on its own behalf in the future, the instruments governing the debt may restrict its ability to pay dividends or make other distributions to us. Distribution of dividends from the Chinese operating companies to foreign shareholders is also subject to a withholding tax. 

 

NOTE P - OPTION AND STOCK ISSUANCE PLANS

 

2013 Stock Option and Stock Issuance Plan

 

On October 30, 2013, the Board of Directors approved the 2013 Stock Plan (the “2013 Plan”) for officers, directors, employees and consultants of the Company.  The stock issuable under the 2013 Plan shall be shares of the Company’s authorized but unissued or reacquired common stock.  The maximum number of shares of common stock which may be issued under the 2013 Plan is 7,500,000 shares.

 

The 2013 Plan is comprised of two separate equity programs, the Options Grant Program, under which eligible persons may be granted options to purchase shares of common stock, and the Stock Issuance Program, under which eligible persons may be issued shares of common stock directly, either through the immediate purchase of such shares or as a bonus for services rendered to the Company. The 2013 Plan provides that the Board of Directors, or a committee of the Board of Directors, will administer it with full authority to determine the identity of the recipients of the options or shares and the number of options or shares.

 

 
F-28

Table of Contents

 

Vaso Corporation and Subsidiaries

 

 NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

 

For the Years Ended December 31, 2022 and 2021

 

During the year ended December 31, 2022, 50,000 shares of common stock were granted, and 90,000 shares were forfeited, under the 2013 Plan.  No shares were withheld for withholding taxes.

 

2016 Stock Option and Stock Issuance Plan

 

On June 15, 2016, the Board of Directors (“Board”) approved the 2016 Stock Plan (the “2016 Plan”) for officers, directors, and senior employees of the Corporation or any subsidiary of the Corporation.  The stock issuable under the 2016 Plan shall be shares of the Company’s authorized but unissued or reacquired common stock.  The maximum number of shares of common stock that may be issued under the 2016 Plan is 7,500,000 shares.

 

The 2016 Plan consists of a Stock Issuance Program, under which eligible persons may, at the discretion of the Board, be issued shares of common stock directly, as a bonus for services rendered or to be rendered to the Corporation or any subsidiary of the Corporation.

 

1,000,000 shares of common stock were granted under the 2016 Plan during the year ended December 31, 2022.

 

2019 Stock Option and Stock Issuance Plan

 

In May 2019, the Board of Directors (“Board”) approved the 2019 Stock Plan (the “2019 Plan”) for officers, directors, and senior employees of the Corporation or any subsidiary of the Corporation. The stock issuable under the 2019 Plan shall be shares of the Company’s authorized but unissued or reacquired common stock. The maximum number of shares of common stock that may be issued under the 2019 Plan is 15,000,000 shares.

 

The 2019 Plan consists of a Stock Issuance Program, under which eligible persons may, at the discretion of the Board, be issued shares of common stock directly, as a bonus for services rendered or to be rendered to the Corporation or any subsidiary of the Corporation.

 

During the year ended December 31, 2022, no shares or options were granted under the 2019 Plan.

 

The following table summarizes non-vested restricted shares under all plans for the year ended December 31, 2022:

 

 

 

Shares Available for Future Issuance

 

 

Unvested shares

 

 

Weighted Average Grant Date Fair Value

 

Balance at December 31, 2020

 

 

11,005,580

 

 

 

4,391,666

 

 

$0.02

 

Authorized

 

 

-

 

 

 

-

 

 

$-

 

Granted

 

 

(90,000)

 

 

90,000

 

 

$0.05

 

Vested

 

 

-

 

 

 

(1,491,666)

 

$0.02

 

Forfeited

 

 

-

 

 

 

-

 

 

$-

 

Expired

 

 

-

 

 

 

-

 

 

$-

 

Balance at December 31, 2021

 

 

10,915,580

 

 

 

2,990,000

 

 

$0.02

 

     Authorized

 

 

-

 

 

 

-

 

 

$-

 

     Granted

 

 

(1,050,000)

 

 

1,050,000

 

 

$0.11

 

     Vested

 

 

-

 

 

 

(1,300,000)

 

$0.02

 

     Forfeited

 

 

90,000

 

 

 

(90,000)

 

$0.05

 

     Expired

 

 

-

 

 

 

-

 

 

$-

 

Balance at December 31, 2022

 

 

9,955,580

 

 

 

2,650,000

 

 

$0.06

 

 

 
F-29

Table of Contents

 

Vaso Corporation and Subsidiaries

 

 NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

 

For the Years Ended December 31, 2022 and 2021 

 

There were 53,558,455 remaining authorized shares of common stock after reserves for all stock option plans.

 

NOTE Q - INCOME TAXES

 

The following is a geographical breakdown of income before the provision for income taxes:

 

 

 

(in thousands)

Year ended December 31,

 

 

 

2022

 

 

2021

 

Domestic

 

$6,823

 

 

$5,720

 

Foreign

 

 

307

 

 

 

531

 

Income before provision for income taxes

 

$7,130

 

 

$6,251

 

 

The provision for income taxes consisted of the following:

 

 

 

(in thousands)

Year ended December 31,

 

 

 

2022

 

 

2021

 

Current provision

 

 

 

 

 

 

Federal

 

$-

 

 

$-

 

State

 

 

36

 

 

 

47

 

Foreign

 

 

9

 

 

 

52

 

Total current provision

 

 

45

 

 

 

99

 

 

 

 

 

 

 

 

 

 

Deferred provision (benefit)

 

 

 

 

 

 

 

 

Federal

 

 

(3,724)

 

 

41

 

State

 

 

(1,064)

 

 

11

 

Foreign

 

 

-

 

 

 

-

 

Total deferred provision (benefit)

 

 

(4,788)

 

 

52

 

 

 

 

 

 

 

 

 

 

Total income tax provision (benefit)

 

$(4,743)

 

$151

 

 

 

 

 

 

 

 

 

 

Effective income tax rate

 

 

66.52%

 

 

2.42%

 

The income tax benefit of $4,743,000 for the year ended December 31, 2022 was due to the partial release of deferred tax asset valuation allowance, offset by $36,000 in state income taxes and $9,000 in foreign taxes.  The income tax provision of $151,000 for the year ended December 31, 2021 was due to $52,000 in foreign taxes, $47,000 in state income taxes and a $52,000 reduction in deferred tax assets.

 

 
F-30

Table of Contents

 

Vaso Corporation and Subsidiaries

 

 NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

 

For the Years Ended December 31, 2022 and 2021

 

The following is a reconciliation of the effective income tax rate to the federal statutory rate:

 

 

 

For the year ended

 

 

 

December 31, 2022

 

 

December 31, 2021

 

 

 

%

 

 

%

 

Federal statutory rate

 

 

21.00

 

 

 

21.00

 

State income taxes

 

 

6.13

 

 

 

2.70

 

Change in valuation allowance relating to operations

 

 

(87.30)

 

 

(21.32)

Foreign tax rate differential

 

 

(0.78)

 

 

(0.84)

R&D credit

 

 

0.54

 

 

 

(0.08)

PPP Loan forgiveness

 

 

-

 

 

 

(11.87)

Nondeductible expenses

 

 

0.20

 

 

 

0.06

 

Other

 

 

(6.31)

 

 

12.77

 

 

 

 

(66.52)

 

 

2.42

 

 

The effective tax rate decreased mainly due to the impact of the partial release of the deferred tax asset valuation allowance and partially offset by impact of PPP loan forgiveness in 2021.

 

As of December 31, 2022, the recorded deferred tax assets were $12,006,000, reflecting a decrease of $1,099,000 during the year ended December 31, 2022, which was offset by a valuation allowance of $4,543,000, reflecting a decrease of $6,226,000. 

 

 
F-31

Table of Contents

 

Vaso Corporation and Subsidiaries

 

 NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

 

For the Years Ended December 31, 2022 and 2021

 

The components of our deferred tax assets and liabilities are summarized as follows:

 

 

 

(in thousands)

 

 

 

December 31, 2022

 

 

December 31, 2021

 

Deferred Tax Assets:

 

 

 

 

 

 

Net operating loss carryforwards

 

$8,367

 

 

$10,015

 

Amortization

 

 

328

 

 

 

343

 

Stock-based compensation

 

 

7

 

 

 

5

 

Allowance for doubtful accounts

 

 

99

 

 

 

125

 

Reserve for slow moving inventory

 

 

46

 

 

 

47

 

Tax credits

 

 

416

 

 

 

454

 

Expense accruals

 

 

908

 

 

 

786

 

Deferred revenue

 

 

1,835

 

 

 

1,330

 

Total gross deferred taxes

 

 

12,006

 

 

 

13,105

 

Valuation allowance

 

 

(4,543)

 

 

(10,769)

Net deferred tax assets

 

 

7,463

 

 

 

2,336

 

 

 

 

 

 

 

 

 

 

Deferred Tax Liabilities:

 

 

 

 

 

 

 

 

Deferred commissions

 

 

(464)

 

 

(325)

Goodwill

 

 

(1,962)

 

 

(1,703)

Depreciation

 

 

(30)

 

 

(89)

Total deferred tax liabilities

 

 

(2,456)

 

 

(2,117)

 

 

 

 

 

 

 

 

 

Total deferred tax assets (liabilities)

 

 

5,007

 

 

 

219

 

 

Recorded as:

 

 

 

 

 

 

       Non-current deferred tax assets

 

 

5,007

 

 

 

219

 

       Non-current deferred tax liabilities

 

 

-

 

 

 

-

 

Total deferred tax assets (liabilities)

 

$5,007

 

 

$219

 

 

The activity in the valuation allowance is set forth below:

 

 

 

(in thousands)

 

 

 

2022

 

 

2021

 

Valuation allowance, January 1,

 

$10,769

 

 

$12,145

 

Partial release of allowance

 

 

(4,840)

 

 

-

 

Change in valuation allowance

 

 

(1,386)

 

 

(1,376)

Valuation allowance, December 31,

 

$4,543

 

 

$10,769

 

 

At December 31, 2022, the Company had net operating loss carryforwards for federal and state income tax purposes of approximately $24 million expiring at various dates from 2022 through 2037 and approximately $7 million with no expiration date.  

 

Under current tax law, the utilization of tax attributes will be restricted if an ownership change, as defined, were to occur. Section 382 of the Internal Revenue Code provides, in general, that if an “ownership change” occurs with respect to a corporation with net operating and other loss carryforwards, such carryforwards will be available to offset taxable income in each taxable year after the ownership change only up to the “Section 382 Limitation” for each year (generally, the product of the fair market value of the corporation’s stock at the time of the ownership change, with certain adjustments, and a specified long-term tax-exempt bond rate at such time). The Company’s ability to use its loss carryforwards will be limited in the event of an ownership change.

 

 
F-32

Table of Contents

 

Vaso Corporation and Subsidiaries

 

 NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

 

For the Years Ended December 31, 2022 and 2021 

 

NOTE R - COMMITMENTS AND CONTINGENCIES

 

Sales representation agreement

 

In October 2021, the Company concluded an amendment of the GEHC Agreement with GEHC, originally signed on May 19, 2010 and previously extended in 2012, 2015 and 2017. The amendment extended the term of the original agreement, which began on July 1, 2010, through December 31, 2026, subject to early termination by GEHC without cause with certain conditions.  Under the agreement, VasoHealthcare is the exclusive representative for the sale of select GEHC diagnostic imaging products to specific market accounts in the 48 contiguous states of the United States and the District of Columbia.  The circumstances under which early termination of the agreement may occur with cause include: not materially achieving certain sales goals, not maintaining a minimum number of sales representatives, and not meeting various legal and GEHC policy requirements.  The Company met all the contractual conditions in 2022.

 

Employment Agreements

 

On May 10, 2019, the Company modified its Employment Agreement with its President and Chief Executive Officer, Dr. Jun Ma, to provide for a five-year term with extensions, unless earlier terminated by the Company, but in no event can it extend beyond May 31, 2026. The Employment Agreement provides for annual compensation of $500,000. Dr. Ma shall be eligible to receive a bonus for each fiscal year during the employment term. The amount and the occasion for payment of such bonus, if any, shall be at the discretion of the Board of Directors. Dr. Ma shall also be eligible for an award under any long-term incentive compensation plan and grants of options and awards of shares of the Company’s stock, as determined at the Board of Directors’ discretion. The Employment Agreement further provides for reimbursement of certain expenses, and certain severance benefits in the event of termination prior to the expiration date of the Employment Agreement.

 

On December 31, 2022, the Company executed an Employment Agreement with the President of its VasoHealthcare subsidiary, Ms. Jane Moen, to provide for a twenty-seven month initial term with extensions, unless earlier terminated by the Company, but in no event can it extend beyond December 31, 2026 or the earlier termination of the GEHC Agreement. The Employment Agreement provides for annual base compensation of $350,000. Ms. Moen shall be eligible to receive bonuses for each fiscal year during the employment term. The amount and the occasion for payment of such bonuses, if any, shall be based on employment status as well as achieving certain operating targets. Ms. Moen shall also be eligible for an award under any long-term incentive compensation plan and grants of options and awards of shares of the Company’s stock, as determined at the Board of Directors’ discretion. The Employment Agreement further provides for reimbursement of certain expenses, and certain severance benefits in the event of termination prior to the expiration date of the Employment Agreement.

 

Licensing and Support Service Agreement

 

In December 2020, NetWolves extended the licensing and support service agreement of its billing system for an additional three years, to expire December 2023.  The agreement provides for monthly recurring charges based on a percentage of billed revenues using these services, which charges aggregated approximately $339,000 and $343,000 for the years ended December 31, 2022 and 2021, respectively.

 

Litigation

 

The Company is currently, and has been in the past, a party to various routine legal proceedings, primarily employee related matters, incident to the ordinary course of business. The Company believes that the outcome of all such pending legal proceedings in the aggregate is unlikely to have a material adverse effect on the business or consolidated financial condition of the Company.

 

 
F-33

Table of Contents

 

Vaso Corporation and Subsidiaries

 

 NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

 

For the Years Ended December 31, 2022 and 2021

 

Foreign operations

 

During the years ended December 31, 2022 and 2021, the Company had and continues to have operations in China. Operating transactions in China are denominated in the Chinese currency called RMB or CNY, which is not freely convertible into foreign currencies.  Operating internationally involves additional risks relating to such things as currency exchange rates, different legal and regulatory environments, political, economic risks relating to the stability or predictability of foreign governments, differences in the manner in which different cultures do business, difficulties in staffing and managing foreign operations, differences in financial reporting, operating difficulties, and other factors.

 

                 Commercial law is still developing in China and there are limited legal precedents to follow in commercial transactions.  There are many tax jurisdictions, each of which may have changing tax laws. Applicable taxes include value added taxes (“VAT”), Enterprise Income Tax, and social (payroll) taxes.  Regulations are often unclear.  Tax declarations (reports) are subject to review and taxing authorities may impose fines, penalties and interest.  These facts create risks in China.  

 

NOTE S - 401(k) PLANS

 

              The Company maintains a defined contribution plan to provide retirement benefits for its employees - the Vaso Corporation 401(k) Plan adopted in April 1997.  As allowed under Section 401(k) of the Internal Revenue Code, the plan provides tax-deferred salary deductions for eligible employees. Employees are eligible to participate in the next quarter enrollment period after employment and participants may make voluntary contributions to the plan up to 80% of their compensation, subject to applicable IRS annual limitations. In the years ended December 31, 2022 and 2021 the Company made discretionary contributions, to match a percentage of employee contributions, of approximately $112,000 and $129,000, respectively.  

 

 
F-34

 

Vaso (QX) (USOTC:VASO)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Vaso (QX) Charts.
Vaso (QX) (USOTC:VASO)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Vaso (QX) Charts.